id	sid	tid	token	lemma	pos
dti-2626	1	1	dti	dti	PROPN
dti-2626	1	2	drug	drug	PROPN
dti-2626	1	3	target	target	NOUN
dti-2626	1	4	insights	insight	NOUN
dti-2626	1	5	2023	2023	NUM
dti-2626	1	6	;	;	PUNCT
dti-2626	1	7	17	17	NUM
dti-2626	1	8	:	:	SYM
dti-2626	1	9	110	110	NUM
dti-2626	1	10	-	-	SYM
dti-2626	1	11	113	113	NUM
dti-2626	1	12	issn	issn	PROPN
dti-2626	1	13	1177	1177	NUM
dti-2626	1	14	-	-	SYM
dti-2626	1	15	3928	3928	NUM
dti-2626	1	16	|	|	ADV
dti-2626	1	17	doi	doi	NOUN
dti-2626	1	18	:	:	PUNCT
dti-2626	1	19	10.33393	10.33393	NUM
dti-2626	1	20	/	/	SYM
dti-2626	1	21	dti.2023.2626	dti.2023.2626	NUM
dti-2626	1	22	case	case	NOUN
dti-2626	1	23	report	report	NOUN
dti-2626	1	24	drug	drug	NOUN
dti-2626	1	25	target	target	NOUN
dti-2626	1	26	insights	insight	NOUN
dti-2626	1	27	issn	issn	VERB
dti-2626	1	28	1177	1177	NUM
dti-2626	1	29	-	-	SYM
dti-2626	1	30	3928	3928	NUM
dti-2626	1	31	www.aboutscience.eu/dti	www.aboutscience.eu/dti	NOUN
dti-2626	1	32	©	©	PROPN
dti-2626	1	33	2022	2022	NUM
dti-2626	1	34	the	the	DET
dti-2626	1	35	authors	author	NOUN
dti-2626	1	36	.	.	PUNCT
dti-2626	2	1	this	this	DET
dti-2626	2	2	article	article	NOUN
dti-2626	2	3	is	be	AUX
dti-2626	2	4	published	publish	VERB
dti-2626	2	5	by	by	ADP
dti-2626	2	6	aboutscience	aboutscience	NOUN
dti-2626	2	7	and	and	CCONJ
dti-2626	2	8	licensed	license	VERB
dti-2626	2	9	under	under	ADP
dti-2626	2	10	creative	creative	ADJ
dti-2626	2	11	commons	common	NOUN
dti-2626	2	12	attribution	attribution	NOUN
dti-2626	2	13	-	-	PUNCT
dti-2626	2	14	noncommercial	noncommercial	ADJ
dti-2626	2	15	4.0	4.0	NUM
dti-2626	2	16	international	international	NOUN
dti-2626	2	17	(	(	PUNCT
dti-2626	2	18	cc	cc	NOUN
dti-2626	2	19	by	by	ADP
dti-2626	2	20	-	-	PUNCT
dti-2626	2	21	nc	nc	PROPN
dti-2626	2	22	4.0	4.0	NUM
dti-2626	2	23	)	)	PUNCT
dti-2626	2	24	.	.	PUNCT
dti-2626	3	1	commercial	commercial	ADJ
dti-2626	3	2	use	use	NOUN
dti-2626	3	3	is	be	AUX
dti-2626	3	4	not	not	PART
dti-2626	3	5	permitted	permit	VERB
dti-2626	3	6	and	and	CCONJ
dti-2626	3	7	is	be	AUX
dti-2626	3	8	subject	subject	ADJ
dti-2626	3	9	to	to	ADP
dti-2626	3	10	publisher	publisher	NOUN
dti-2626	3	11	’s	’s	PART
dti-2626	3	12	permissions	permission	NOUN
dti-2626	3	13	.	.	PUNCT
dti-2626	4	1	full	full	ADJ
dti-2626	4	2	information	information	NOUN
dti-2626	4	3	is	be	AUX
dti-2626	4	4	available	available	ADJ
dti-2626	4	5	at	at	ADP
dti-2626	4	6	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-2626	4	7	first	first	ADJ
dti-2626	4	8	-	-	PUNCT
dti-2626	4	9	line	line	NOUN
dti-2626	4	10	tepotinib	tepotinib	NOUN
dti-2626	4	11	for	for	ADP
dti-2626	4	12	a	a	DET
dti-2626	4	13	very	very	ADV
dti-2626	4	14	elderly	elderly	ADJ
dti-2626	4	15	patient	patient	NOUN
dti-2626	4	16	with	with	ADP
dti-2626	4	17	metastatic	metastatic	ADJ
dti-2626	4	18	nsclc	nsclc	NOUN
dti-2626	4	19	harboring	harboring	NOUN
dti-2626	4	20	met	meet	VERB
dti-2626	4	21	exon	exon	NOUN
dti-2626	4	22	14	14	NUM
dti-2626	4	23	skipping	skip	VERB
dti-2626	4	24	mutation	mutation	NOUN
dti-2626	4	25	and	and	CCONJ
dti-2626	4	26	high	high	ADJ
dti-2626	4	27	pd	pd	PROPN
dti-2626	4	28	-	-	PUNCT
dti-2626	4	29	l1	l1	PROPN
dti-2626	4	30	expression	expression	NOUN
dti-2626	4	31	alessandro	alessandro	PROPN
dti-2626	4	32	inno1	inno1	PROPN
dti-2626	4	33	,	,	PUNCT
dti-2626	4	34	giuseppe	giuseppe	PROPN
dti-2626	4	35	bogina2	bogina2	PROPN
dti-2626	4	36	,	,	PUNCT
dti-2626	4	37	giulio	giulio	PROPN
dti-2626	4	38	settanni2	settanni2	PROPN
dti-2626	4	39	,	,	PUNCT
dti-2626	4	40	matteo	matteo	PROPN
dti-2626	4	41	salgarello3	salgarello3	PROPN
dti-2626	4	42	,	,	PUNCT
dti-2626	4	43	giovanni	giovanni	PROPN
dti-2626	4	44	foti4	foti4	PROPN
dti-2626	4	45	,	,	PUNCT
dti-2626	4	46	carlo	carlo	PROPN
dti-2626	4	47	pomari5	pomari5	PROPN
dti-2626	4	48	,	,	PUNCT
dti-2626	4	49	vincenzo	vincenzo	PROPN
dti-2626	4	50	picece1	picece1	PROPN
dti-2626	4	51	,	,	PUNCT
dti-2626	4	52	stefania	stefania	PROPN
dti-2626	4	53	gori1	gori1	PROPN
dti-2626	4	54	1medical	1medical	NUM
dti-2626	4	55	oncology	oncology	NOUN
dti-2626	4	56	unit	unit	NOUN
dti-2626	4	57	,	,	PUNCT
dti-2626	4	58	irccs	ircc	VERB
dti-2626	4	59	ospedale	ospedale	PROPN
dti-2626	4	60	sacro	sacro	PROPN
dti-2626	4	61	cuore	cuore	PROPN
dti-2626	4	62	don	don	PROPN
dti-2626	4	63	calabria	calabria	PROPN
dti-2626	4	64	,	,	PUNCT
dti-2626	4	65	negrar	negrar	PROPN
dti-2626	4	66	di	di	X
dti-2626	4	67	valpolicella	valpolicella	PROPN
dti-2626	4	68	(	(	PUNCT
dti-2626	4	69	vr	vr	PROPN
dti-2626	4	70	)	)	PUNCT
dti-2626	4	71	italy	italy	PROPN
dti-2626	4	72	2pathology	2pathology	PROPN
dti-2626	4	73	unit	unit	NOUN
dti-2626	4	74	,	,	PUNCT
dti-2626	4	75	irccs	ircc	VERB
dti-2626	4	76	ospedale	ospedale	PROPN
dti-2626	4	77	sacro	sacro	PROPN
dti-2626	4	78	cuore	cuore	PROPN
dti-2626	4	79	don	don	PROPN
dti-2626	4	80	calabria	calabria	PROPN
dti-2626	4	81	,	,	PUNCT
dti-2626	4	82	negrar	negrar	PROPN
dti-2626	4	83	di	di	X
dti-2626	4	84	valpolicella	valpolicella	PROPN
dti-2626	4	85	(	(	PUNCT
dti-2626	4	86	vr	vr	PROPN
dti-2626	4	87	)	)	PUNCT
dti-2626	4	88	italy	italy	PROPN
dti-2626	4	89	3nuclear	3nuclear	NUM
dti-2626	4	90	medicine	medicine	NOUN
dti-2626	4	91	unit	unit	NOUN
dti-2626	4	92	,	,	PUNCT
dti-2626	4	93	irccs	ircc	VERB
dti-2626	4	94	ospedale	ospedale	PROPN
dti-2626	4	95	sacro	sacro	PROPN
dti-2626	4	96	cuore	cuore	PROPN
dti-2626	4	97	don	don	PROPN
dti-2626	4	98	calabria	calabria	PROPN
dti-2626	4	99	,	,	PUNCT
dti-2626	4	100	negrar	negrar	PROPN
dti-2626	4	101	di	di	X
dti-2626	4	102	valpolicella	valpolicella	PROPN
dti-2626	4	103	(	(	PUNCT
dti-2626	4	104	vr	vr	PROPN
dti-2626	4	105	)	)	PUNCT
dti-2626	4	106	italy	italy	PROPN
dti-2626	4	107	4radiology	4radiology	PROPN
dti-2626	4	108	unit	unit	NOUN
dti-2626	4	109	,	,	PUNCT
dti-2626	4	110	irccs	ircc	VERB
dti-2626	4	111	ospedale	ospedale	PROPN
dti-2626	4	112	sacro	sacro	PROPN
dti-2626	4	113	cuore	cuore	PROPN
dti-2626	4	114	don	don	PROPN
dti-2626	4	115	calabria	calabria	PROPN
dti-2626	4	116	,	,	PUNCT
dti-2626	4	117	negrar	negrar	PROPN
dti-2626	4	118	di	di	X
dti-2626	4	119	valpolicella	valpolicella	PROPN
dti-2626	4	120	(	(	PUNCT
dti-2626	4	121	vr	vr	PROPN
dti-2626	4	122	)	)	PUNCT
dti-2626	4	123	italy	italy	PROPN
dti-2626	4	124	5pulmonology	5pulmonology	NUM
dti-2626	4	125	and	and	CCONJ
dti-2626	4	126	thoracic	thoracic	NOUN
dti-2626	4	127	endoscopy	endoscopy	NOUN
dti-2626	4	128	unit	unit	NOUN
dti-2626	4	129	,	,	PUNCT
dti-2626	4	130	irccs	ircc	VERB
dti-2626	4	131	ospedale	ospedale	PROPN
dti-2626	4	132	sacro	sacro	PROPN
dti-2626	4	133	cuore	cuore	PROPN
dti-2626	4	134	don	don	PROPN
dti-2626	4	135	calabria	calabria	PROPN
dti-2626	4	136	,	,	PUNCT
dti-2626	4	137	negrar	negrar	PROPN
dti-2626	4	138	di	di	X
dti-2626	4	139	valpolicella	valpolicella	PROPN
dti-2626	4	140	(	(	PUNCT
dti-2626	4	141	vr	vr	PROPN
dti-2626	4	142	)	)	PUNCT
dti-2626	4	143	italy	italy	PROPN
dti-2626	4	144	abstract	abstract	ADJ
dti-2626	4	145	optimal	optimal	ADJ
dti-2626	4	146	treatment	treatment	NOUN
dti-2626	4	147	for	for	ADP
dti-2626	4	148	metastatic	metastatic	ADJ
dti-2626	4	149	non	non	ADJ
dti-2626	4	150	-	-	ADJ
dti-2626	4	151	small	small	ADJ
dti-2626	4	152	cell	cell	NOUN
dti-2626	4	153	lung	lung	NOUN
dti-2626	4	154	cancer	cancer	NOUN
dti-2626	4	155	(	(	PUNCT
dti-2626	4	156	nsclc	nsclc	NOUN
dti-2626	4	157	)	)	PUNCT
dti-2626	4	158	with	with	ADP
dti-2626	4	159	mesenchymal	mesenchymal	ADJ
dti-2626	4	160	epithelial	epithelial	ADJ
dti-2626	4	161	transition	transition	NOUN
dti-2626	4	162	gene	gene	NOUN
dti-2626	4	163	(	(	PUNCT
dti-2626	4	164	met	meet	VERB
dti-2626	4	165	)	)	PUNCT
dti-2626	4	166	exon	exon	NOUN
dti-2626	4	167	14	14	NUM
dti-2626	4	168	skipping	skip	VERB
dti-2626	4	169	mutation	mutation	NOUN
dti-2626	4	170	has	have	AUX
dti-2626	4	171	not	not	PART
dti-2626	4	172	been	be	AUX
dti-2626	4	173	established	establish	VERB
dti-2626	4	174	yet	yet	ADV
dti-2626	4	175	.	.	PUNCT
dti-2626	5	1	met	meet	VERB
dti-2626	5	2	inhibitors	inhibitor	NOUN
dti-2626	5	3	were	be	AUX
dti-2626	5	4	demonstrated	demonstrate	VERB
dti-2626	5	5	to	to	PART
dti-2626	5	6	be	be	AUX
dti-2626	5	7	effective	effective	ADJ
dti-2626	5	8	and	and	CCONJ
dti-2626	5	9	tolerated	tolerate	VERB
dti-2626	5	10	in	in	ADP
dti-2626	5	11	patients	patient	NOUN
dti-2626	5	12	with	with	ADP
dti-2626	5	13	this	this	DET
dti-2626	5	14	condition	condition	NOUN
dti-2626	5	15	,	,	PUNCT
dti-2626	5	16	while	while	SCONJ
dti-2626	5	17	evidence	evidence	NOUN
dti-2626	5	18	on	on	ADP
dti-2626	5	19	safety	safety	NOUN
dti-2626	5	20	and	and	CCONJ
dti-2626	5	21	efficacy	efficacy	NOUN
dti-2626	5	22	of	of	ADP
dti-2626	5	23	immunotherapy	immunotherapy	NOUN
dti-2626	5	24	and/or	and/or	CCONJ
dti-2626	5	25	chemotherapy	chemotherapy	NOUN
dti-2626	5	26	in	in	ADP
dti-2626	5	27	this	this	DET
dti-2626	5	28	population	population	NOUN
dti-2626	5	29	is	be	AUX
dti-2626	5	30	limited	limited	ADJ
dti-2626	5	31	.	.	PUNCT
dti-2626	6	1	here	here	ADV
dti-2626	6	2	we	we	PRON
dti-2626	6	3	report	report	VERB
dti-2626	6	4	the	the	DET
dti-2626	6	5	case	case	NOUN
dti-2626	6	6	of	of	ADP
dti-2626	6	7	an	an	DET
dti-2626	6	8	86	86	NUM
dti-2626	6	9	-	-	PUNCT
dti-2626	6	10	year	year	NOUN
dti-2626	6	11	-	-	PUNCT
dti-2626	6	12	old	old	ADJ
dti-2626	6	13	male	male	NOUN
dti-2626	6	14	with	with	ADP
dti-2626	6	15	metastatic	metastatic	ADJ
dti-2626	6	16	nsclc	nsclc	NOUN
dti-2626	6	17	harboring	harboring	NOUN
dti-2626	6	18	met	meet	VERB
dti-2626	6	19	exon	exon	NOUN
dti-2626	6	20	14	14	NUM
dti-2626	6	21	skipping	skip	VERB
dti-2626	6	22	mutation	mutation	NOUN
dti-2626	6	23	and	and	CCONJ
dti-2626	6	24	with	with	ADP
dti-2626	6	25	high	high	ADJ
dti-2626	6	26	programmed	program	VERB
dti-2626	6	27	cell	cell	NOUN
dti-2626	6	28	death	death	NOUN
dti-2626	6	29	ligand	ligand	NOUN
dti-2626	6	30	1	1	NUM
dti-2626	6	31	(	(	PUNCT
dti-2626	6	32	pd	pd	NOUN
dti-2626	6	33	-	-	PUNCT
dti-2626	6	34	l1	l1	NOUN
dti-2626	6	35	)	)	PUNCT
dti-2626	6	36	expression	expression	NOUN
dti-2626	6	37	(	(	PUNCT
dti-2626	6	38	tumor	tumor	NOUN
dti-2626	6	39	proportion	proportion	NOUN
dti-2626	6	40	score	score	NOUN
dti-2626	6	41	≥50	≥50	NUM
dti-2626	6	42	%	%	NOUN
dti-2626	6	43	)	)	PUNCT
dti-2626	6	44	.	.	PUNCT
dti-2626	7	1	the	the	DET
dti-2626	7	2	patient	patient	NOUN
dti-2626	7	3	received	receive	VERB
dti-2626	7	4	the	the	DET
dti-2626	7	5	met	meet	VERB
dti-2626	7	6	inhibitor	inhibitor	NOUN
dti-2626	7	7	tepotinib	tepotinib	NOUN
dti-2626	7	8	as	as	ADP
dti-2626	7	9	first	first	ADJ
dti-2626	7	10	-	-	PUNCT
dti-2626	7	11	line	line	NOUN
dti-2626	7	12	treatment	treatment	NOUN
dti-2626	7	13	,	,	PUNCT
dti-2626	7	14	achieving	achieve	VERB
dti-2626	7	15	a	a	DET
dti-2626	7	16	partial	partial	ADJ
dti-2626	7	17	response	response	NOUN
dti-2626	7	18	,	,	PUNCT
dti-2626	7	19	with	with	ADP
dti-2626	7	20	g2	g2	PROPN
dti-2626	7	21	peripheral	peripheral	ADJ
dti-2626	7	22	edema	edema	NOUN
dti-2626	7	23	as	as	ADP
dti-2626	7	24	adverse	adverse	ADJ
dti-2626	7	25	event	event	NOUN
dti-2626	7	26	that	that	PRON
dti-2626	7	27	was	be	AUX
dti-2626	7	28	successfully	successfully	ADV
dti-2626	7	29	managed	manage	VERB
dti-2626	7	30	with	with	ADP
dti-2626	7	31	temporary	temporary	ADJ
dti-2626	7	32	discontinuation	discontinuation	NOUN
dti-2626	7	33	,	,	PUNCT
dti-2626	7	34	dose	dose	NOUN
dti-2626	7	35	reduction	reduction	NOUN
dti-2626	7	36	,	,	PUNCT
dti-2626	7	37	diuretics	diuretic	NOUN
dti-2626	7	38	and	and	CCONJ
dti-2626	7	39	physical	physical	ADJ
dti-2626	7	40	therapy	therapy	NOUN
dti-2626	7	41	.	.	PUNCT
dti-2626	8	1	after	after	ADP
dti-2626	8	2	31	31	NUM
dti-2626	8	3	months	month	NOUN
dti-2626	8	4	,	,	PUNCT
dti-2626	8	5	the	the	DET
dti-2626	8	6	patient	patient	NOUN
dti-2626	8	7	is	be	AUX
dti-2626	8	8	still	still	ADV
dti-2626	8	9	receiving	receive	VERB
dti-2626	8	10	tepotinib	tepotinib	NOUN
dti-2626	8	11	,	,	PUNCT
dti-2626	8	12	with	with	ADP
dti-2626	8	13	an	an	DET
dti-2626	8	14	ongoing	ongoing	ADJ
dti-2626	8	15	response	response	NOUN
dti-2626	8	16	.	.	PUNCT
dti-2626	9	1	tepotinib	tepotinib	NOUN
dti-2626	9	2	is	be	AUX
dti-2626	9	3	a	a	DET
dti-2626	9	4	valuable	valuable	ADJ
dti-2626	9	5	therapeutic	therapeutic	ADJ
dti-2626	9	6	option	option	NOUN
dti-2626	9	7	for	for	ADP
dti-2626	9	8	first	first	ADJ
dti-2626	9	9	-	-	PUNCT
dti-2626	9	10	line	line	NOUN
dti-2626	9	11	treatment	treatment	NOUN
dti-2626	9	12	of	of	ADP
dti-2626	9	13	older	old	ADJ
dti-2626	9	14	patients	patient	NOUN
dti-2626	9	15	with	with	ADP
dti-2626	9	16	nsclc	nsclc	NOUN
dti-2626	9	17	harboring	harboring	NOUN
dti-2626	9	18	met	meet	VERB
dti-2626	9	19	exon	exon	NOUN
dti-2626	9	20	14	14	NUM
dti-2626	9	21	skipping	skip	VERB
dti-2626	9	22	mutation	mutation	NOUN
dti-2626	9	23	,	,	PUNCT
dti-2626	9	24	even	even	ADV
dti-2626	9	25	in	in	ADP
dti-2626	9	26	the	the	DET
dti-2626	9	27	presence	presence	NOUN
dti-2626	9	28	of	of	ADP
dti-2626	9	29	high	high	ADJ
dti-2626	9	30	pd	pd	PROPN
dti-2626	9	31	-	-	PROPN
dti-2626	9	32	l1	l1	PROPN
dti-2626	9	33	expression	expression	NOUN
dti-2626	9	34	.	.	PUNCT
dti-2626	10	1	keywords	keyword	NOUN
dti-2626	10	2	:	:	PUNCT
dti-2626	10	3	elderly	elderly	ADJ
dti-2626	10	4	,	,	PUNCT
dti-2626	10	5	first	first	ADJ
dti-2626	10	6	-	-	PUNCT
dti-2626	10	7	line	line	NOUN
dti-2626	10	8	treatment	treatment	NOUN
dti-2626	10	9	,	,	PUNCT
dti-2626	10	10	met	meet	VERB
dti-2626	10	11	14	14	NUM
dti-2626	10	12	-	-	PUNCT
dti-2626	10	13	exon	exon	NOUN
dti-2626	10	14	skipping	skip	VERB
dti-2626	10	15	mutation	mutation	NOUN
dti-2626	10	16	,	,	PUNCT
dti-2626	10	17	met	meet	VERB
dti-2626	10	18	inhibitor	inhibitor	NOUN
dti-2626	10	19	,	,	PUNCT
dti-2626	10	20	non	non	ADJ
dti-2626	10	21	-	-	ADJ
dti-2626	10	22	small	small	ADJ
dti-2626	10	23	cell	cell	NOUN
dti-2626	10	24	lung	lung	NOUN
dti-2626	10	25	cancer	cancer	NOUN
dti-2626	10	26	,	,	PUNCT
dti-2626	10	27	tepotinib	tepotinib	NOUN
dti-2626	10	28	received	receive	VERB
dti-2626	10	29	:	:	PUNCT
dti-2626	10	30	july	july	PROPN
dti-2626	10	31	3	3	NUM
dti-2626	10	32	,	,	PUNCT
dti-2626	10	33	2023	2023	NUM
dti-2626	10	34	accepted	accept	VERB
dti-2626	10	35	:	:	PUNCT
dti-2626	10	36	september	september	PROPN
dti-2626	10	37	19	19	NUM
dti-2626	10	38	,	,	PUNCT
dti-2626	10	39	2023	2023	NUM
dti-2626	10	40	published	publish	VERB
dti-2626	10	41	online	online	ADV
dti-2626	10	42	:	:	PUNCT
dti-2626	10	43	october	october	PROPN
dti-2626	10	44	6	6	NUM
dti-2626	10	45	,	,	PUNCT
dti-2626	10	46	2023	2023	NUM
dti-2626	10	47	corresponding	correspond	VERB
dti-2626	10	48	author	author	NOUN
dti-2626	10	49	:	:	PUNCT
dti-2626	10	50	alessandro	alessandro	PROPN
dti-2626	10	51	inno	inno	PROPN
dti-2626	10	52	medical	medical	ADJ
dti-2626	10	53	oncology	oncology	NOUN
dti-2626	10	54	irccs	ircc	VERB
dti-2626	10	55	ospedale	ospedale	PROPN
dti-2626	10	56	sacro	sacro	PROPN
dti-2626	10	57	cuore	cuore	PROPN
dti-2626	10	58	don	don	PROPN
dti-2626	10	59	calabria	calabria	PROPN
dti-2626	10	60	via	via	ADP
dti-2626	10	61	don	don	PROPN
dti-2626	10	62	a.	a.	NOUN
dti-2626	10	63	sempreboni	sempreboni	NOUN
dti-2626	10	64	5	5	NUM
dti-2626	10	65	37024	37024	NUM
dti-2626	10	66	negrar	negrar	PROPN
dti-2626	10	67	di	di	X
dti-2626	10	68	valpolicella	valpolicella	PROPN
dti-2626	10	69	(	(	PUNCT
dti-2626	10	70	vr	vr	PROPN
dti-2626	10	71	)	)	PUNCT
dti-2626	10	72	italy	italy	PROPN
dti-2626	10	73	alessandro.inno@sacrocuore.it	alessandro.inno@sacrocuore.it	PROPN
dti-2626	10	74	patients	patient	NOUN
dti-2626	10	75	(	(	PUNCT
dti-2626	10	76	2,3	2,3	NUM
dti-2626	10	77	)	)	PUNCT
dti-2626	10	78	.	.	PUNCT
dti-2626	11	1	based	base	VERB
dti-2626	11	2	on	on	ADP
dti-2626	11	3	these	these	DET
dti-2626	11	4	results	result	NOUN
dti-2626	11	5	,	,	PUNCT
dti-2626	11	6	tepotinib	tepotinib	NOUN
dti-2626	11	7	was	be	AUX
dti-2626	11	8	approved	approve	VERB
dti-2626	11	9	by	by	ADP
dti-2626	11	10	the	the	DET
dti-2626	11	11	food	food	NOUN
dti-2626	11	12	and	and	CCONJ
dti-2626	11	13	drug	drug	NOUN
dti-2626	11	14	administration	administration	NOUN
dti-2626	11	15	for	for	ADP
dti-2626	11	16	the	the	DET
dti-2626	11	17	treatment	treatment	NOUN
dti-2626	11	18	of	of	ADP
dti-2626	11	19	patients	patient	NOUN
dti-2626	11	20	with	with	ADP
dti-2626	11	21	metastatic	metastatic	ADJ
dti-2626	11	22	nsclc	nsclc	NOUN
dti-2626	11	23	harboring	harboring	NOUN
dti-2626	11	24	metex14	metex14	NOUN
dti-2626	11	25	skipping	skip	VERB
dti-2626	11	26	mutation	mutation	NOUN
dti-2626	11	27	regardless	regardless	ADV
dti-2626	11	28	of	of	ADP
dti-2626	11	29	the	the	DET
dti-2626	11	30	line	line	NOUN
dti-2626	11	31	of	of	ADP
dti-2626	11	32	therapy	therapy	NOUN
dti-2626	11	33	(	(	PUNCT
dti-2626	11	34	4	4	NUM
dti-2626	11	35	)	)	PUNCT
dti-2626	11	36	,	,	PUNCT
dti-2626	11	37	whereas	whereas	SCONJ
dti-2626	11	38	the	the	DET
dti-2626	11	39	european	european	PROPN
dti-2626	11	40	medicines	medicines	PROPN
dti-2626	11	41	agency	agency	NOUN
dti-2626	11	42	(	(	PUNCT
dti-2626	11	43	ema	ema	PROPN
dti-2626	11	44	)	)	PUNCT
dti-2626	11	45	approved	approve	VERB
dti-2626	11	46	tepotinib	tepotinib	NOUN
dti-2626	11	47	only	only	ADV
dti-2626	11	48	for	for	ADP
dti-2626	11	49	patients	patient	NOUN
dti-2626	11	50	previously	previously	ADV
dti-2626	11	51	treated	treat	VERB
dti-2626	11	52	with	with	ADP
dti-2626	11	53	immunotherapy	immunotherapy	NOUN
dti-2626	11	54	and/or	and/or	CCONJ
dti-2626	11	55	platinum	platinum	NOUN
dti-2626	11	56	-	-	PUNCT
dti-2626	11	57	based	base	VERB
dti-2626	11	58	chemotherapy	chemotherapy	NOUN
dti-2626	11	59	(	(	PUNCT
dti-2626	11	60	5	5	NUM
dti-2626	11	61	)	)	PUNCT
dti-2626	11	62	.	.	PUNCT
dti-2626	12	1	here	here	ADV
dti-2626	12	2	we	we	PRON
dti-2626	12	3	report	report	VERB
dti-2626	12	4	the	the	DET
dti-2626	12	5	case	case	NOUN
dti-2626	12	6	of	of	ADP
dti-2626	12	7	an	an	DET
dti-2626	12	8	86	86	NUM
dti-2626	12	9	-	-	PUNCT
dti-2626	12	10	year	year	NOUN
dti-2626	12	11	-	-	PUNCT
dti-2626	12	12	old	old	ADJ
dti-2626	12	13	male	male	NOUN
dti-2626	12	14	with	with	ADP
dti-2626	12	15	metex14	metex14	NOUN
dti-2626	12	16	-	-	PUNCT
dti-2626	12	17	mutated	mutate	VERB
dti-2626	12	18	metastatic	metastatic	ADJ
dti-2626	12	19	nsclc	nsclc	NOUN
dti-2626	12	20	and	and	CCONJ
dti-2626	12	21	concomitant	concomitant	ADJ
dti-2626	12	22	high	high	ADJ
dti-2626	12	23	programmed	program	VERB
dti-2626	12	24	cell	cell	NOUN
dti-2626	12	25	death	death	NOUN
dti-2626	12	26	ligand	ligand	NOUN
dti-2626	12	27	1	1	NUM
dti-2626	12	28	(	(	PUNCT
dti-2626	12	29	pd	pd	NOUN
dti-2626	12	30	-	-	PUNCT
dti-2626	12	31	l1	l1	NOUN
dti-2626	12	32	)	)	PUNCT
dti-2626	12	33	expression	expression	NOUN
dti-2626	12	34	treated	treat	VERB
dti-2626	12	35	with	with	ADP
dti-2626	12	36	first	first	ADJ
dti-2626	12	37	-	-	PUNCT
dti-2626	12	38	line	line	NOUN
dti-2626	12	39	tepotinib	tepotinib	NOUN
dti-2626	12	40	that	that	PRON
dti-2626	12	41	achieved	achieve	VERB
dti-2626	12	42	a	a	DET
dti-2626	12	43	deep	deep	ADJ
dti-2626	12	44	and	and	CCONJ
dti-2626	12	45	durable	durable	ADJ
dti-2626	12	46	response	response	NOUN
dti-2626	12	47	with	with	ADP
dti-2626	12	48	manageable	manageable	ADJ
dti-2626	12	49	toxicity	toxicity	NOUN
dti-2626	12	50	.	.	PUNCT
dti-2626	13	1	case	case	NOUN
dti-2626	13	2	description	description	NOUN
dti-2626	13	3	following	follow	VERB
dti-2626	13	4	an	an	DET
dti-2626	13	5	accidental	accidental	ADJ
dti-2626	13	6	fall	fall	NOUN
dti-2626	13	7	,	,	PUNCT
dti-2626	13	8	a	a	DET
dti-2626	13	9	former	former	ADJ
dti-2626	13	10	86	86	NUM
dti-2626	13	11	-	-	PUNCT
dti-2626	13	12	year	year	NOUN
dti-2626	13	13	-	-	PUNCT
dti-2626	13	14	old	old	ADJ
dti-2626	13	15	male	male	NOUN
dti-2626	13	16	smoker	smoker	NOUN
dti-2626	13	17	underwent	undergo	VERB
dti-2626	13	18	a	a	DET
dti-2626	13	19	head	head	NOUN
dti-2626	13	20	and	and	CCONJ
dti-2626	13	21	chest	chest	NOUN
dti-2626	13	22	computed	compute	VERB
dti-2626	13	23	tomography	tomography	NOUN
dti-2626	13	24	(	(	PUNCT
dti-2626	13	25	ct	ct	NOUN
dti-2626	13	26	)	)	PUNCT
dti-2626	13	27	scan	scan	NOUN
dti-2626	13	28	,	,	PUNCT
dti-2626	13	29	which	which	PRON
dti-2626	13	30	showed	show	VERB
dti-2626	13	31	a	a	DET
dti-2626	13	32	lung	lung	NOUN
dti-2626	13	33	tumor	tumor	NOUN
dti-2626	13	34	in	in	ADP
dti-2626	13	35	the	the	DET
dti-2626	13	36	right	right	ADV
dti-2626	13	37	lower	low	ADJ
dti-2626	13	38	lobe	lobe	PROPN
dti-2626	13	39	.	.	PUNCT
dti-2626	14	1	the	the	DET
dti-2626	14	2	18f	18f	NUM
dti-2626	14	3	-	-	PUNCT
dti-2626	14	4	fluorodeoxyglucose	fluorodeoxyglucose	PROPN
dti-2626	14	5	(	(	PUNCT
dti-2626	14	6	fdg	fdg	PROPN
dti-2626	14	7	)	)	PUNCT
dti-2626	14	8	positron	positron	NOUN
dti-2626	14	9	emission	emission	NOUN
dti-2626	14	10	tomography	tomography	NOUN
dti-2626	14	11	(	(	PUNCT
dti-2626	14	12	pet)/ct	pet)/ct	PROPN
dti-2626	14	13	confirmed	confirm	VERB
dti-2626	14	14	the	the	DET
dti-2626	14	15	presence	presence	NOUN
dti-2626	14	16	of	of	ADP
dti-2626	14	17	a	a	DET
dti-2626	14	18	lung	lung	NOUN
dti-2626	14	19	tumor	tumor	NOUN
dti-2626	14	20	and	and	CCONJ
dti-2626	14	21	showed	show	VERB
dti-2626	14	22	bone	bone	NOUN
dti-2626	14	23	,	,	PUNCT
dti-2626	14	24	left	leave	VERB
dti-2626	14	25	adrenal	adrenal	ADJ
dti-2626	14	26	and	and	CCONJ
dti-2626	14	27	peritoneal	peritoneal	ADJ
dti-2626	14	28	metastases	metastasis	NOUN
dti-2626	14	29	(	(	PUNCT
dti-2626	14	30	fig	fig	NOUN
dti-2626	14	31	.	.	NOUN
dti-2626	14	32	1	1	NUM
dti-2626	14	33	)	)	PUNCT
dti-2626	14	34	.	.	PUNCT
dti-2626	15	1	stage	stage	NOUN
dti-2626	15	2	was	be	AUX
dti-2626	15	3	ct1c	ct1c	PROPN
dti-2626	15	4	n0	n0	X
dti-2626	15	5	m1c	m1c	PROPN
dti-2626	15	6	,	,	PUNCT
dti-2626	15	7	ivb	ivb	NOUN
dti-2626	15	8	according	accord	VERB
dti-2626	15	9	to	to	ADP
dti-2626	15	10	the	the	DET
dti-2626	15	11	american	american	ADJ
dti-2626	15	12	introduction	introduction	NOUN
dti-2626	15	13	mesenchymal	mesenchymal	ADJ
dti-2626	15	14	epithelial	epithelial	ADJ
dti-2626	15	15	transition	transition	NOUN
dti-2626	15	16	gene	gene	NOUN
dti-2626	15	17	(	(	PUNCT
dti-2626	15	18	met	meet	VERB
dti-2626	15	19	)	)	PUNCT
dti-2626	15	20	exon	exon	NOUN
dti-2626	15	21	14	14	NUM
dti-2626	15	22	(	(	PUNCT
dti-2626	15	23	metex14	metex14	NOUN
dti-2626	15	24	)	)	PUNCT
dti-2626	15	25	skipping	skip	VERB
dti-2626	15	26	mutations	mutation	NOUN
dti-2626	15	27	occur	occur	VERB
dti-2626	15	28	in	in	ADP
dti-2626	15	29	approximately	approximately	ADV
dti-2626	15	30	3	3	NUM
dti-2626	15	31	-	-	SYM
dti-2626	15	32	4	4	NUM
dti-2626	15	33	%	%	NOUN
dti-2626	15	34	of	of	ADP
dti-2626	15	35	non	non	ADJ
dti-2626	15	36	-	-	ADJ
dti-2626	15	37	small	small	ADJ
dti-2626	15	38	cell	cell	NOUN
dti-2626	15	39	lung	lung	NOUN
dti-2626	15	40	cancer	cancer	NOUN
dti-2626	15	41	(	(	PUNCT
dti-2626	15	42	nsclc	nsclc	NOUN
dti-2626	15	43	)	)	PUNCT
dti-2626	15	44	(	(	PUNCT
dti-2626	15	45	1	1	NUM
dti-2626	15	46	)	)	PUNCT
dti-2626	15	47	.	.	PUNCT
dti-2626	16	1	in	in	ADP
dti-2626	16	2	the	the	DET
dti-2626	16	3	vision	vision	NOUN
dti-2626	16	4	trial	trial	NOUN
dti-2626	16	5	,	,	PUNCT
dti-2626	16	6	a	a	DET
dti-2626	16	7	phase	phase	NOUN
dti-2626	16	8	2	2	NUM
dti-2626	16	9	,	,	PUNCT
dti-2626	16	10	non	non	ADJ
dti-2626	16	11	-	-	ADJ
dti-2626	16	12	randomized	randomized	ADJ
dti-2626	16	13	open	open	ADJ
dti-2626	16	14	-	-	PUNCT
dti-2626	16	15	label	label	NOUN
dti-2626	16	16	study	study	NOUN
dti-2626	16	17	,	,	PUNCT
dti-2626	16	18	the	the	DET
dti-2626	16	19	met	meet	VERB
dti-2626	16	20	inhibitor	inhibitor	NOUN
dti-2626	16	21	tepotinib	tepotinib	NOUN
dti-2626	16	22	achieved	achieve	VERB
dti-2626	16	23	a	a	DET
dti-2626	16	24	response	response	NOUN
dti-2626	16	25	rate	rate	NOUN
dti-2626	16	26	of	of	ADP
dti-2626	16	27	51.4	51.4	NUM
dti-2626	16	28	%	%	NOUN
dti-2626	16	29	and	and	CCONJ
dti-2626	16	30	a	a	DET
dti-2626	16	31	median	median	ADJ
dti-2626	16	32	duration	duration	NOUN
dti-2626	16	33	of	of	ADP
dti-2626	16	34	response	response	NOUN
dti-2626	16	35	(	(	PUNCT
dti-2626	16	36	dor	dor	NOUN
dti-2626	16	37	)	)	PUNCT
dti-2626	16	38	of	of	ADP
dti-2626	16	39	18	18	NUM
dti-2626	16	40	months	month	NOUN
dti-2626	16	41	among	among	ADP
dti-2626	16	42	313	313	NUM
dti-2626	16	43	patients	patient	NOUN
dti-2626	16	44	with	with	ADP
dti-2626	16	45	metex14	metex14	NOUN
dti-2626	16	46	mutant	mutant	NOUN
dti-2626	16	47	advanced	advanced	ADJ
dti-2626	16	48	/	/	SYM
dti-2626	16	49	metastatic	metastatic	ADJ
dti-2626	16	50	nsclc	nsclc	NOUN
dti-2626	16	51	,	,	PUNCT
dti-2626	16	52	both	both	PRON
dti-2626	16	53	treatmet	treatmet	NOUN
dti-2626	16	54	-	-	PUNCT
dti-2626	16	55	naïve	naïve	ADJ
dti-2626	16	56	(	(	PUNCT
dti-2626	16	57	n	n	NOUN
dti-2626	16	58	=	=	SYM
dti-2626	16	59	164	164	NUM
dti-2626	16	60	)	)	PUNCT
dti-2626	16	61	and	and	CCONJ
dti-2626	16	62	previously	previously	ADV
dti-2626	16	63	treated	treat	VERB
dti-2626	16	64	(	(	PUNCT
dti-2626	16	65	n	n	NOUN
dti-2626	16	66	=	=	SYM
dti-2626	16	67	149	149	NUM
dti-2626	16	68	)	)	PUNCT
dti-2626	16	69	dti_2626	dti_2626	NUM
dti-2626	16	70	_	_	PRON
dti-2626	17	1	v4.indd	v4.indd	PROPN
dti-2626	18	1	110dti_2626	110dti_2626	NUM
dti-2626	18	2	_	_	PUNCT
dti-2626	18	3	v4.indd	v4.indd	PROPN
dti-2626	18	4	110	110	NUM
dti-2626	18	5	10/23/2023	10/23/2023	NUM
dti-2626	18	6	10:06:56	10:06:56	NUM
dti-2626	18	7	am10/23/2023	am10/23/2023	NOUN
dti-2626	18	8	10:06:56	10:06:56	NUM
dti-2626	18	9	am	be	AUX
dti-2626	18	10	inno	inno	PROPN
dti-2626	18	11	et	et	PROPN
dti-2626	18	12	al	al	PROPN
dti-2626	18	13	drug	drug	PROPN
dti-2626	18	14	target	target	NOUN
dti-2626	18	15	insights	insight	NOUN
dti-2626	18	16	2023	2023	NUM
dti-2626	18	17	;	;	PUNCT
dti-2626	18	18	17	17	NUM
dti-2626	18	19	:	:	SYM
dti-2626	18	20	111	111	NUM
dti-2626	19	1	©	©	PROPN
dti-2626	19	2	2023	2023	NUM
dti-2626	19	3	the	the	DET
dti-2626	19	4	authors	author	NOUN
dti-2626	19	5	.	.	PUNCT
dti-2626	20	1	published	publish	VERB
dti-2626	20	2	by	by	ADP
dti-2626	20	3	aboutscience	aboutscience	NOUN
dti-2626	20	4	www.aboutscience.eu	www.aboutscience.eu	PROPN
dti-2626	20	5	joint	joint	PROPN
dti-2626	20	6	committee	committee	NOUN
dti-2626	20	7	on	on	ADP
dti-2626	20	8	cancer	cancer	NOUN
dti-2626	20	9	(	(	PUNCT
dti-2626	20	10	ajcc	ajcc	PROPN
dti-2626	20	11	)	)	PUNCT
dti-2626	20	12	8th	8th	NOUN
dti-2626	20	13	edition	edition	NOUN
dti-2626	20	14	.	.	PUNCT
dti-2626	21	1	the	the	DET
dti-2626	21	2	pathology	pathology	NOUN
dti-2626	21	3	examination	examination	NOUN
dti-2626	21	4	of	of	ADP
dti-2626	21	5	a	a	DET
dti-2626	21	6	ct	ct	ADV
dti-2626	21	7	-	-	PUNCT
dti-2626	21	8	guided	guide	VERB
dti-2626	21	9	biopsy	biopsy	NOUN
dti-2626	21	10	of	of	ADP
dti-2626	21	11	the	the	DET
dti-2626	21	12	lung	lung	NOUN
dti-2626	21	13	mass	mass	NOUN
dti-2626	21	14	diagnosed	diagnose	VERB
dti-2626	21	15	lung	lung	NOUN
dti-2626	21	16	adenocarcinoma	adenocarcinoma	NOUN
dti-2626	21	17	with	with	ADP
dti-2626	21	18	sarcomatoid	sarcomatoid	NOUN
dti-2626	21	19	transformation	transformation	NOUN
dti-2626	21	20	.	.	PUNCT
dti-2626	22	1	the	the	DET
dti-2626	22	2	immunohistochemical	immunohistochemical	ADJ
dti-2626	22	3	evaluation	evaluation	NOUN
dti-2626	22	4	showed	show	VERB
dti-2626	22	5	high	high	ADJ
dti-2626	22	6	pd	pd	PROPN
dti-2626	22	7	-	-	PUNCT
dti-2626	22	8	l1	l1	PROPN
dti-2626	22	9	expression	expression	NOUN
dti-2626	22	10	with	with	ADP
dti-2626	22	11	a	a	DET
dti-2626	22	12	tumor	tumor	NOUN
dti-2626	22	13	proportion	proportion	NOUN
dti-2626	22	14	score	score	NOUN
dti-2626	22	15	(	(	PUNCT
dti-2626	22	16	tps	tps	NOUN
dti-2626	22	17	)	)	PUNCT
dti-2626	22	18	≥50	≥50	NUM
dti-2626	22	19	%	%	NOUN
dti-2626	22	20	,	,	PUNCT
dti-2626	22	21	and	and	CCONJ
dti-2626	22	22	next	next	ADJ
dti-2626	22	23	-	-	PUNCT
dti-2626	22	24	generation	generation	NOUN
dti-2626	22	25	sequencing	sequencing	NOUN
dti-2626	22	26	(	(	PUNCT
dti-2626	22	27	ngs	ng	NOUN
dti-2626	22	28	)	)	PUNCT
dti-2626	22	29	found	find	VERB
dti-2626	22	30	metex14	metex14	NOUN
dti-2626	22	31	skipping	skip	VERB
dti-2626	22	32	mutation	mutation	NOUN
dti-2626	22	33	.	.	PUNCT
dti-2626	23	1	comorbidities	comorbiditie	NOUN
dti-2626	23	2	included	include	VERB
dti-2626	23	3	trigeminal	trigeminal	ADJ
dti-2626	23	4	neuralgia	neuralgia	NOUN
dti-2626	23	5	,	,	PUNCT
dti-2626	23	6	prostatic	prostatic	ADJ
dti-2626	23	7	hypertrophy	hypertrophy	NOUN
dti-2626	23	8	,	,	PUNCT
dti-2626	23	9	eye	eye	NOUN
dti-2626	23	10	maculopathy	maculopathy	ADJ
dti-2626	23	11	,	,	PUNCT
dti-2626	23	12	and	and	CCONJ
dti-2626	23	13	bilateral	bilateral	ADJ
dti-2626	23	14	knee	knee	NOUN
dti-2626	23	15	and	and	CCONJ
dti-2626	23	16	right	right	ADJ
dti-2626	23	17	hip	hip	NOUN
dti-2626	23	18	replacement	replacement	NOUN
dti-2626	23	19	.	.	PUNCT
dti-2626	24	1	first	first	ADJ
dti-2626	24	2	-	-	PUNCT
dti-2626	24	3	line	line	NOUN
dti-2626	24	4	tepotinib	tepotinib	NOUN
dti-2626	24	5	500	500	NUM
dti-2626	24	6	mg	mg	NUM
dti-2626	24	7	/	/	SYM
dti-2626	24	8	day	day	NOUN
dti-2626	24	9	was	be	AUX
dti-2626	24	10	started	start	VERB
dti-2626	24	11	through	through	ADP
dti-2626	24	12	an	an	DET
dti-2626	24	13	early	early	ADJ
dti-2626	24	14	access	access	NOUN
dti-2626	24	15	program	program	NOUN
dti-2626	24	16	.	.	PUNCT
dti-2626	25	1	the	the	DET
dti-2626	25	2	patient	patient	NOUN
dti-2626	25	3	achieved	achieve	VERB
dti-2626	25	4	partial	partial	ADJ
dti-2626	25	5	response	response	NOUN
dti-2626	25	6	at	at	ADP
dti-2626	25	7	the	the	DET
dti-2626	25	8	first	first	ADJ
dti-2626	25	9	tumor	tumor	NOUN
dti-2626	25	10	assessment	assessment	NOUN
dti-2626	25	11	after	after	ADP
dti-2626	25	12	3	3	NUM
dti-2626	25	13	months	month	NOUN
dti-2626	25	14	of	of	ADP
dti-2626	25	15	treatment	treatment	NOUN
dti-2626	25	16	.	.	PUNCT
dti-2626	26	1	further	further	ADJ
dti-2626	26	2	response	response	NOUN
dti-2626	26	3	was	be	AUX
dti-2626	26	4	observed	observe	VERB
dti-2626	26	5	at	at	ADP
dti-2626	26	6	months	month	NOUN
dti-2626	26	7	6	6	NUM
dti-2626	26	8	,	,	PUNCT
dti-2626	26	9	9	9	NUM
dti-2626	26	10	and	and	CCONJ
dti-2626	26	11	12	12	NUM
dti-2626	26	12	,	,	PUNCT
dti-2626	26	13	then	then	ADV
dti-2626	26	14	stable	stable	ADJ
dti-2626	26	15	disease	disease	NOUN
dti-2626	26	16	was	be	AUX
dti-2626	26	17	observed	observe	VERB
dti-2626	26	18	(	(	PUNCT
dti-2626	26	19	fig	fig	NOUN
dti-2626	26	20	.	.	PUNCT
dti-2626	27	1	2	2	NUM
dti-2626	27	2	)	)	PUNCT
dti-2626	27	3	.	.	PUNCT
dti-2626	28	1	during	during	ADP
dti-2626	28	2	the	the	DET
dti-2626	28	3	treatment	treatment	NOUN
dti-2626	28	4	,	,	PUNCT
dti-2626	28	5	the	the	DET
dti-2626	28	6	patient	patient	NOUN
dti-2626	28	7	was	be	AUX
dti-2626	28	8	diagnosed	diagnose	VERB
dti-2626	28	9	also	also	ADV
dti-2626	28	10	with	with	ADP
dti-2626	28	11	a	a	DET
dti-2626	28	12	prostate	prostate	NOUN
dti-2626	28	13	carcinoma	carcinoma	NOUN
dti-2626	28	14	(	(	PUNCT
dti-2626	28	15	stage	stage	NOUN
dti-2626	28	16	ct2	ct2	PROPN
dti-2626	28	17	cn0	cn0	PROPN
dti-2626	28	18	,	,	PUNCT
dti-2626	28	19	gleason	gleason	PROPN
dti-2626	28	20	score	score	VERB
dti-2626	28	21	4	4	NUM
dti-2626	28	22	+	+	NOUN
dti-2626	28	23	4	4	NUM
dti-2626	28	24	)	)	PUNCT
dti-2626	28	25	,	,	PUNCT
dti-2626	28	26	therefore	therefore	ADV
dti-2626	28	27	androgen	androgen	NOUN
dti-2626	28	28	deprivation	deprivation	NOUN
dti-2626	28	29	therapy	therapy	NOUN
dti-2626	28	30	was	be	AUX
dti-2626	28	31	added	add	VERB
dti-2626	28	32	,	,	PUNCT
dti-2626	28	33	without	without	ADP
dti-2626	28	34	safety	safety	NOUN
dti-2626	28	35	concerns	concern	NOUN
dti-2626	28	36	.	.	PUNCT
dti-2626	29	1	after	after	ADP
dti-2626	29	2	6	6	NUM
dti-2626	29	3	months	month	NOUN
dti-2626	29	4	of	of	ADP
dti-2626	29	5	treatment	treatment	NOUN
dti-2626	29	6	with	with	ADP
dti-2626	29	7	tepotinib	tepotinib	NOUN
dti-2626	29	8	,	,	PUNCT
dti-2626	29	9	the	the	DET
dti-2626	29	10	patient	patient	NOUN
dti-2626	29	11	developed	develop	VERB
dti-2626	29	12	treatment	treatment	NOUN
dti-2626	29	13	-	-	PUNCT
dti-2626	29	14	related	relate	VERB
dti-2626	29	15	g2	g2	PROPN
dti-2626	29	16	peripheral	peripheral	ADJ
dti-2626	29	17	edema	edema	NOUN
dti-2626	29	18	;	;	PUNCT
dti-2626	29	19	therefore	therefore	ADV
dti-2626	29	20	,	,	PUNCT
dti-2626	29	21	tepotinib	tepotinib	NOUN
dti-2626	29	22	was	be	AUX
dti-2626	29	23	temporarily	temporarily	ADV
dti-2626	29	24	discontinued	discontinue	VERB
dti-2626	29	25	,	,	PUNCT
dti-2626	29	26	and	and	CCONJ
dti-2626	29	27	diuretics	diuretic	NOUN
dti-2626	29	28	were	be	AUX
dti-2626	29	29	administered	administer	VERB
dti-2626	29	30	,	,	PUNCT
dti-2626	29	31	with	with	ADP
dti-2626	29	32	complete	complete	ADJ
dti-2626	29	33	regression	regression	NOUN
dti-2626	29	34	of	of	ADP
dti-2626	29	35	edema	edema	NOUN
dti-2626	29	36	.	.	PUNCT
dti-2626	30	1	tepotinib	tepotinib	NOUN
dti-2626	30	2	was	be	AUX
dti-2626	30	3	then	then	ADV
dti-2626	30	4	restarted	restart	VERB
dti-2626	30	5	at	at	ADP
dti-2626	30	6	250	250	NUM
dti-2626	30	7	mg	mg	NUM
dti-2626	30	8	/	/	SYM
dti-2626	30	9	day	day	NOUN
dti-2626	30	10	.	.	PUNCT
dti-2626	31	1	after	after	ADP
dti-2626	31	2	16	16	NUM
dti-2626	31	3	months	month	NOUN
dti-2626	31	4	of	of	ADP
dti-2626	31	5	treatment	treatment	NOUN
dti-2626	31	6	,	,	PUNCT
dti-2626	31	7	however	however	ADV
dti-2626	31	8	,	,	PUNCT
dti-2626	31	9	tepotinib	tepotinib	NOUN
dti-2626	31	10	was	be	AUX
dti-2626	31	11	discontinued	discontinue	VERB
dti-2626	31	12	again	again	ADV
dti-2626	31	13	due	due	ADP
dti-2626	31	14	to	to	ADP
dti-2626	31	15	recurrent	recurrent	VERB
dti-2626	31	16	g2	g2	PROPN
dti-2626	31	17	peripheral	peripheral	ADJ
dti-2626	31	18	edema	edema	NOUN
dti-2626	31	19	.	.	PUNCT
dti-2626	32	1	the	the	DET
dti-2626	32	2	patient	patient	NOUN
dti-2626	32	3	received	receive	VERB
dti-2626	32	4	a	a	DET
dti-2626	32	5	further	further	ADJ
dti-2626	32	6	course	course	NOUN
dti-2626	32	7	of	of	ADP
dti-2626	32	8	diuretics	diuretic	NOUN
dti-2626	32	9	combined	combine	VERB
dti-2626	32	10	with	with	ADP
dti-2626	32	11	physical	physical	ADJ
dti-2626	32	12	therapy	therapy	NOUN
dti-2626	32	13	(	(	PUNCT
dti-2626	32	14	i.e.	i.e.	X
dti-2626	32	15	,	,	PUNCT
dti-2626	32	16	compression	compression	NOUN
dti-2626	32	17	stockings	stocking	NOUN
dti-2626	32	18	,	,	PUNCT
dti-2626	32	19	retrograde	retrograde	ADJ
dti-2626	32	20	massage	massage	NOUN
dti-2626	32	21	)	)	PUNCT
dti-2626	32	22	,	,	PUNCT
dti-2626	32	23	achieving	achieve	VERB
dti-2626	32	24	edema	edema	NOUN
dti-2626	32	25	improvement	improvement	NOUN
dti-2626	32	26	at	at	ADP
dti-2626	32	27	g1	g1	PROPN
dti-2626	32	28	;	;	PUNCT
dti-2626	32	29	then	then	ADV
dti-2626	32	30	,	,	PUNCT
dti-2626	32	31	tepotinib	tepotinib	NOUN
dti-2626	32	32	was	be	AUX
dti-2626	32	33	restarted	restart	VERB
dti-2626	32	34	at	at	ADP
dti-2626	32	35	250	250	NUM
dti-2626	32	36	mg	mg	NUM
dti-2626	32	37	/	/	SYM
dti-2626	32	38	day	day	NOUN
dti-2626	32	39	.	.	PUNCT
dti-2626	33	1	after	after	ADP
dti-2626	33	2	23	23	NUM
dti-2626	33	3	months	month	NOUN
dti-2626	33	4	of	of	ADP
dti-2626	33	5	treatment	treatment	NOUN
dti-2626	33	6	,	,	PUNCT
dti-2626	33	7	tepotinib	tepotinib	NOUN
dti-2626	33	8	was	be	AUX
dti-2626	33	9	reduced	reduce	VERB
dti-2626	33	10	at	at	ADP
dti-2626	33	11	250	250	NUM
dti-2626	33	12	mg	mg	NOUN
dti-2626	33	13	every	every	DET
dti-2626	33	14	other	other	ADJ
dti-2626	33	15	day	day	NOUN
dti-2626	33	16	because	because	SCONJ
dti-2626	33	17	of	of	ADP
dti-2626	33	18	worsening	worsen	VERB
dti-2626	33	19	edema	edema	NOUN
dti-2626	33	20	,	,	PUNCT
dti-2626	33	21	and	and	CCONJ
dti-2626	33	22	it	it	PRON
dti-2626	33	23	is	be	AUX
dti-2626	33	24	currently	currently	ADV
dti-2626	33	25	ongoing	ongoing	ADJ
dti-2626	33	26	(	(	PUNCT
dti-2626	33	27	after	after	ADP
dti-2626	33	28	31	31	NUM
dti-2626	33	29	months	month	NOUN
dti-2626	33	30	)	)	PUNCT
dti-2626	33	31	.	.	PUNCT
dti-2626	34	1	discussion	discussion	NOUN
dti-2626	34	2	for	for	ADP
dti-2626	34	3	patients	patient	NOUN
dti-2626	34	4	with	with	ADP
dti-2626	34	5	metastatic	metastatic	ADJ
dti-2626	34	6	nsclc	nsclc	NOUN
dti-2626	34	7	without	without	ADP
dti-2626	34	8	driver	driver	NOUN
dti-2626	34	9	molecular	molecular	ADJ
dti-2626	34	10	alterations	alteration	NOUN
dti-2626	34	11	,	,	PUNCT
dti-2626	34	12	immunotherapy	immunotherapy	NOUN
dti-2626	34	13	with	with	ADP
dti-2626	34	14	or	or	CCONJ
dti-2626	34	15	without	without	ADP
dti-2626	34	16	chemotherapy	chemotherapy	NOUN
dti-2626	34	17	represents	represent	VERB
dti-2626	34	18	the	the	DET
dti-2626	34	19	standard	standard	NOUN
dti-2626	34	20	of	of	ADP
dti-2626	34	21	care	care	NOUN
dti-2626	34	22	in	in	ADP
dti-2626	34	23	the	the	DET
dti-2626	34	24	first	first	ADJ
dti-2626	34	25	-	-	PUNCT
dti-2626	34	26	line	line	NOUN
dti-2626	34	27	setting	setting	NOUN
dti-2626	34	28	(	(	PUNCT
dti-2626	34	29	6	6	NUM
dti-2626	34	30	)	)	PUNCT
dti-2626	34	31	.	.	PUNCT
dti-2626	35	1	particularly	particularly	ADV
dti-2626	35	2	,	,	PUNCT
dti-2626	35	3	for	for	ADP
dti-2626	35	4	patients	patient	NOUN
dti-2626	35	5	with	with	ADP
dti-2626	35	6	high	high	ADJ
dti-2626	35	7	pd	pd	PROPN
dti-2626	35	8	-	-	PUNCT
dti-2626	35	9	l1	l1	PROPN
dti-2626	35	10	expression	expression	NOUN
dti-2626	35	11	(	(	PUNCT
dti-2626	35	12	tps	tps	NOUN
dti-2626	35	13	≥50	≥50	NUM
dti-2626	35	14	%	%	NOUN
dti-2626	35	15	)	)	PUNCT
dti-2626	35	16	,	,	PUNCT
dti-2626	35	17	immunotherapy	immunotherapy	NOUN
dti-2626	35	18	alone	alone	ADV
dti-2626	35	19	with	with	ADP
dti-2626	35	20	anti	anti	ADJ
dti-2626	35	21	-	-	ADJ
dti-2626	35	22	pd-(l)1	pd-(l)1	NOUN
dti-2626	35	23	antibodies	antibodie	VERB
dti-2626	35	24	as	as	ADP
dti-2626	35	25	single	single	ADJ
dti-2626	35	26	agent	agent	NOUN
dti-2626	35	27	represents	represent	VERB
dti-2626	35	28	the	the	DET
dti-2626	35	29	treatment	treatment	NOUN
dti-2626	35	30	of	of	ADP
dti-2626	35	31	choice	choice	NOUN
dti-2626	35	32	.	.	PUNCT
dti-2626	36	1	indeed	indeed	ADV
dti-2626	36	2	,	,	PUNCT
dti-2626	36	3	in	in	ADP
dti-2626	36	4	the	the	DET
dti-2626	36	5	phase	phase	NOUN
dti-2626	36	6	iii	iii	NOUN
dti-2626	36	7	keynote-024	keynote-024	NOUN
dti-2626	36	8	trial	trial	NOUN
dti-2626	36	9	,	,	PUNCT
dti-2626	36	10	the	the	DET
dti-2626	36	11	anti	anti	ADJ
dti-2626	36	12	-	-	ADJ
dti-2626	36	13	pd-1	pd-1	ADJ
dti-2626	36	14	antibody	antibody	NOUN
dti-2626	36	15	pembrolizumab	pembrolizumab	NOUN
dti-2626	36	16	as	as	ADP
dti-2626	36	17	single	single	ADJ
dti-2626	36	18	agent	agent	NOUN
dti-2626	36	19	achieved	achieve	VERB
dti-2626	36	20	a	a	DET
dti-2626	36	21	median	median	ADJ
dti-2626	36	22	overall	overall	ADJ
dti-2626	36	23	survival	survival	NOUN
dti-2626	36	24	(	(	PUNCT
dti-2626	36	25	os	os	NOUN
dti-2626	36	26	)	)	PUNCT
dti-2626	36	27	of	of	ADP
dti-2626	36	28	26.3	26.3	NUM
dti-2626	36	29	months	month	NOUN
dti-2626	36	30	,	,	PUNCT
dti-2626	36	31	and	and	CCONJ
dti-2626	36	32	a	a	DET
dti-2626	36	33	5	5	NUM
dti-2626	36	34	-	-	PUNCT
dti-2626	36	35	year	year	NOUN
dti-2626	36	36	os	os	NOUN
dti-2626	36	37	rate	rate	NOUN
dti-2626	36	38	of	of	ADP
dti-2626	36	39	31.9	31.9	NUM
dti-2626	36	40	%	%	NOUN
dti-2626	36	41	,	,	PUNCT
dti-2626	36	42	compared	compare	VERB
dti-2626	36	43	respectively	respectively	ADV
dti-2626	36	44	with	with	ADP
dti-2626	36	45	13.4	13.4	NUM
dti-2626	36	46	months	month	NOUN
dti-2626	36	47	and	and	CCONJ
dti-2626	36	48	16.3	16.3	NUM
dti-2626	36	49	%	%	NOUN
dti-2626	36	50	of	of	ADP
dti-2626	36	51	platinumbased	platinumbase	VERB
dti-2626	36	52	chemotherapy	chemotherapy	NOUN
dti-2626	36	53	as	as	ADP
dti-2626	36	54	first	first	ADJ
dti-2626	36	55	-	-	PUNCT
dti-2626	36	56	line	line	NOUN
dti-2626	36	57	treatment	treatment	NOUN
dti-2626	36	58	of	of	ADP
dti-2626	36	59	metastatic	metastatic	ADJ
dti-2626	36	60	fig	fig	NOUN
dti-2626	36	61	.	.	PUNCT
dti-2626	37	1	1	1	NUM
dti-2626	37	2	positron	positron	NOUN
dti-2626	37	3	emission	emission	NOUN
dti-2626	37	4	tomography	tomography	NOUN
dti-2626	37	5	-	-	PUNCT
dti-2626	37	6	computed	compute	VERB
dti-2626	37	7	tomography	tomography	NOUN
dti-2626	37	8	(	(	PUNCT
dti-2626	37	9	pet	pet	NOUN
dti-2626	37	10	-	-	PUNCT
dti-2626	37	11	ct	ct	NOUN
dti-2626	37	12	)	)	PUNCT
dti-2626	37	13	scan	scan	NOUN
dti-2626	37	14	showing	show	VERB
dti-2626	37	15	primary	primary	ADJ
dti-2626	37	16	lung	lung	NOUN
dti-2626	37	17	tumor	tumor	NOUN
dti-2626	37	18	(	(	PUNCT
dti-2626	37	19	a	a	NOUN
dti-2626	37	20	)	)	PUNCT
dti-2626	37	21	,	,	PUNCT
dti-2626	37	22	bone	bone	NOUN
dti-2626	37	23	metastasis	metastasis	NOUN
dti-2626	37	24	in	in	ADP
dti-2626	37	25	the	the	DET
dti-2626	37	26	first	first	ADJ
dti-2626	37	27	right	right	ADJ
dti-2626	37	28	rib	rib	NOUN
dti-2626	37	29	(	(	PUNCT
dti-2626	37	30	b	b	NOUN
dti-2626	37	31	)	)	PUNCT
dti-2626	37	32	,	,	PUNCT
dti-2626	37	33	and	and	CCONJ
dti-2626	37	34	peritoneal	peritoneal	ADJ
dti-2626	37	35	metastasis	metastasis	NOUN
dti-2626	37	36	(	(	PUNCT
dti-2626	37	37	c	c	NOUN
dti-2626	37	38	)	)	PUNCT
dti-2626	37	39	.	.	PUNCT
dti-2626	38	1	fig	fig	NOUN
dti-2626	38	2	.	.	PUNCT
dti-2626	39	1	2	2	NUM
dti-2626	39	2	computed	compute	VERB
dti-2626	39	3	tomography	tomography	NOUN
dti-2626	39	4	(	(	PUNCT
dti-2626	39	5	ct	ct	NOUN
dti-2626	39	6	)	)	PUNCT
dti-2626	39	7	scan	scan	NOUN
dti-2626	39	8	showing	show	VERB
dti-2626	39	9	,	,	PUNCT
dti-2626	39	10	respecively	respecively	ADV
dti-2626	39	11	,	,	PUNCT
dti-2626	39	12	primary	primary	ADJ
dti-2626	39	13	lung	lung	NOUN
dti-2626	39	14	tumor	tumor	NOUN
dti-2626	39	15	and	and	CCONJ
dti-2626	39	16	peritoneal	peritoneal	ADJ
dti-2626	39	17	metastasis	metastasis	NOUN
dti-2626	39	18	at	at	ADP
dti-2626	39	19	baseline	baseline	PROPN
dti-2626	39	20	(	(	PUNCT
dti-2626	39	21	a	a	DET
dti-2626	39	22	,	,	PUNCT
dti-2626	39	23	d	d	NOUN
dti-2626	39	24	)	)	PUNCT
dti-2626	39	25	,	,	PUNCT
dti-2626	39	26	after	after	ADP
dti-2626	39	27	12	12	NUM
dti-2626	39	28	weeks	week	NOUN
dti-2626	39	29	(	(	PUNCT
dti-2626	39	30	b	b	NOUN
dti-2626	39	31	,	,	PUNCT
dti-2626	39	32	e	e	NOUN
dti-2626	39	33	)	)	PUNCT
dti-2626	39	34	and	and	CCONJ
dti-2626	39	35	1	1	NUM
dti-2626	39	36	year	year	NOUN
dti-2626	39	37	(	(	PUNCT
dti-2626	39	38	c	c	NOUN
dti-2626	39	39	,	,	PUNCT
dti-2626	39	40	f	f	NOUN
dti-2626	39	41	)	)	PUNCT
dti-2626	39	42	of	of	ADP
dti-2626	39	43	tepotinib	tepotinib	NOUN
dti-2626	39	44	.	.	PUNCT
dti-2626	40	1	dti_2626	dti_2626	NUM
dti-2626	40	2	_	_	PUNCT
dti-2626	40	3	v4.indd	v4.indd	NOUN
dti-2626	41	1	111dti_2626	111dti_2626	NUM
dti-2626	41	2	_	_	PUNCT
dti-2626	41	3	v4.indd	v4.indd	PROPN
dti-2626	41	4	111	111	NUM
dti-2626	41	5	10/23/2023	10/23/2023	NUM
dti-2626	41	6	10:06:57	10:06:57	NUM
dti-2626	41	7	am10/23/2023	am10/23/2023	NOUN
dti-2626	41	8	10:06:57	10:06:57	NUM
dti-2626	41	9	am	be	AUX
dti-2626	41	10	first	first	ADJ
dti-2626	41	11	-	-	PUNCT
dti-2626	41	12	line	line	NOUN
dti-2626	41	13	tepotinib	tepotinib	NOUN
dti-2626	41	14	for	for	SCONJ
dti-2626	41	15	met	meet	VERB
dti-2626	41	16	mutant	mutant	ADJ
dti-2626	41	17	nsclc	nsclc	NOUN
dti-2626	41	18	with	with	ADP
dti-2626	41	19	high	high	ADJ
dti-2626	41	20	pd	pd	PROPN
dti-2626	41	21	-	-	PROPN
dti-2626	41	22	l1	l1	PROPN
dti-2626	41	23	in	in	ADP
dti-2626	41	24	an	an	DET
dti-2626	41	25	old	old	ADJ
dti-2626	41	26	patient112	patient112	PROPN
dti-2626	41	27	©	©	PROPN
dti-2626	41	28	2023	2023	NUM
dti-2626	41	29	the	the	DET
dti-2626	41	30	authors	author	NOUN
dti-2626	41	31	.	.	PUNCT
dti-2626	42	1	drug	drug	NOUN
dti-2626	42	2	target	target	NOUN
dti-2626	42	3	insights	insight	NOUN
dti-2626	42	4	issn	issn	VERB
dti-2626	42	5	1177	1177	NUM
dti-2626	42	6	-	-	SYM
dti-2626	42	7	3928	3928	NUM
dti-2626	42	8	www.aboutscience.eu/dti	www.aboutscience.eu/dti	NOUN
dti-2626	42	9	nsclc	nsclc	NOUN
dti-2626	42	10	with	with	ADP
dti-2626	42	11	tps	tps	NOUN
dti-2626	42	12	≥50	≥50	NUM
dti-2626	42	13	%	%	NOUN
dti-2626	42	14	(	(	PUNCT
dti-2626	42	15	7	7	NUM
dti-2626	42	16	)	)	PUNCT
dti-2626	42	17	.	.	PUNCT
dti-2626	43	1	similar	similar	ADJ
dti-2626	43	2	results	result	NOUN
dti-2626	43	3	are	be	AUX
dti-2626	43	4	available	available	ADJ
dti-2626	43	5	also	also	ADV
dti-2626	43	6	for	for	ADP
dti-2626	43	7	other	other	ADJ
dti-2626	43	8	anti	anti	ADJ
dti-2626	43	9	-	-	ADJ
dti-2626	43	10	pd-(l)1	pd-(l)1	ADJ
dti-2626	43	11	agents	agent	NOUN
dti-2626	43	12	(	(	PUNCT
dti-2626	43	13	8,9	8,9	NUM
dti-2626	43	14	)	)	PUNCT
dti-2626	43	15	.	.	PUNCT
dti-2626	44	1	moreover	moreover	ADV
dti-2626	44	2	,	,	PUNCT
dti-2626	44	3	the	the	DET
dti-2626	44	4	addition	addition	NOUN
dti-2626	44	5	of	of	ADP
dti-2626	44	6	immunotherapy	immunotherapy	NOUN
dti-2626	44	7	to	to	ADP
dti-2626	44	8	the	the	DET
dti-2626	44	9	first	first	ADJ
dti-2626	44	10	-	-	PUNCT
dti-2626	44	11	line	line	NOUN
dti-2626	44	12	platinum	platinum	NOUN
dti-2626	44	13	-	-	PUNCT
dti-2626	44	14	based	base	VERB
dti-2626	44	15	chemotherapy	chemotherapy	NOUN
dti-2626	44	16	improved	improve	VERB
dti-2626	44	17	survival	survival	NOUN
dti-2626	44	18	over	over	ADP
dti-2626	44	19	chemotherapy	chemotherapy	NOUN
dti-2626	44	20	alone	alone	ADV
dti-2626	44	21	,	,	PUNCT
dti-2626	44	22	regardless	regardless	ADV
dti-2626	44	23	of	of	ADP
dti-2626	44	24	pd	pd	PROPN
dti-2626	44	25	-	-	PUNCT
dti-2626	44	26	l1	l1	PROPN
dti-2626	44	27	expression	expression	NOUN
dti-2626	44	28	levels	level	NOUN
dti-2626	44	29	(	(	PUNCT
dti-2626	44	30	10	10	NUM
dti-2626	44	31	)	)	PUNCT
dti-2626	44	32	.	.	PUNCT
dti-2626	45	1	for	for	ADP
dti-2626	45	2	patients	patient	NOUN
dti-2626	45	3	with	with	ADP
dti-2626	45	4	nsclc	nsclc	NOUN
dti-2626	45	5	harboring	harboring	NOUN
dti-2626	45	6	metex14	metex14	NOUN
dti-2626	45	7	skipping	skip	VERB
dti-2626	45	8	mutations	mutation	NOUN
dti-2626	45	9	,	,	PUNCT
dti-2626	45	10	however	however	ADV
dti-2626	45	11	,	,	PUNCT
dti-2626	45	12	the	the	DET
dti-2626	45	13	optimal	optimal	ADJ
dti-2626	45	14	treatment	treatment	NOUN
dti-2626	45	15	strategy	strategy	NOUN
dti-2626	45	16	has	have	AUX
dti-2626	45	17	not	not	PART
dti-2626	45	18	yet	yet	ADV
dti-2626	45	19	been	be	AUX
dti-2626	45	20	established	establish	VERB
dti-2626	45	21	.	.	PUNCT
dti-2626	46	1	in	in	ADP
dti-2626	46	2	fact	fact	NOUN
dti-2626	46	3	,	,	PUNCT
dti-2626	46	4	there	there	PRON
dti-2626	46	5	are	be	VERB
dti-2626	46	6	no	no	DET
dti-2626	46	7	data	datum	NOUN
dti-2626	46	8	from	from	ADP
dti-2626	46	9	randomized	randomized	ADJ
dti-2626	46	10	studies	study	NOUN
dti-2626	46	11	on	on	ADP
dti-2626	46	12	the	the	DET
dti-2626	46	13	efficacy	efficacy	NOUN
dti-2626	46	14	of	of	ADP
dti-2626	46	15	immunotherapy	immunotherapy	NOUN
dti-2626	46	16	and/or	and/or	CCONJ
dti-2626	46	17	chemotherapy	chemotherapy	NOUN
dti-2626	46	18	in	in	ADP
dti-2626	46	19	the	the	DET
dti-2626	46	20	specific	specific	ADJ
dti-2626	46	21	population	population	NOUN
dti-2626	46	22	of	of	ADP
dti-2626	46	23	patients	patient	NOUN
dti-2626	46	24	with	with	ADP
dti-2626	46	25	metex14	metex14	NOUN
dti-2626	46	26	mutant	mutant	ADJ
dti-2626	46	27	nsclc	nsclc	NOUN
dti-2626	46	28	.	.	PUNCT
dti-2626	47	1	retrospective	retrospective	ADJ
dti-2626	47	2	studies	study	NOUN
dti-2626	47	3	showed	show	VERB
dti-2626	47	4	conflicting	conflicting	ADJ
dti-2626	47	5	results	result	NOUN
dti-2626	47	6	,	,	PUNCT
dti-2626	47	7	with	with	ADP
dti-2626	47	8	some	some	DET
dti-2626	47	9	studies	study	NOUN
dti-2626	47	10	suggesting	suggest	VERB
dti-2626	47	11	a	a	DET
dti-2626	47	12	limited	limited	ADJ
dti-2626	47	13	activity	activity	NOUN
dti-2626	47	14	of	of	ADP
dti-2626	47	15	immunotherapy	immunotherapy	NOUN
dti-2626	47	16	in	in	ADP
dti-2626	47	17	this	this	DET
dti-2626	47	18	population	population	NOUN
dti-2626	47	19	regardless	regardless	ADV
dti-2626	47	20	of	of	ADP
dti-2626	47	21	pd	pd	PROPN
dti-2626	47	22	-	-	PUNCT
dti-2626	47	23	l1	l1	PROPN
dti-2626	47	24	expression	expression	NOUN
dti-2626	47	25	level	level	NOUN
dti-2626	47	26	(	(	PUNCT
dti-2626	47	27	11,12	11,12	NUM
dti-2626	47	28	)	)	PUNCT
dti-2626	47	29	,	,	PUNCT
dti-2626	47	30	whereas	whereas	SCONJ
dti-2626	47	31	other	other	ADJ
dti-2626	47	32	studies	study	NOUN
dti-2626	47	33	reported	report	VERB
dti-2626	47	34	a	a	DET
dti-2626	47	35	similar	similar	ADJ
dti-2626	47	36	activity	activity	NOUN
dti-2626	47	37	of	of	ADP
dti-2626	47	38	immunotherapy	immunotherapy	NOUN
dti-2626	47	39	among	among	ADP
dti-2626	47	40	met	meet	VERB
dti-2626	47	41	mutant	mutant	ADJ
dti-2626	47	42	and	and	CCONJ
dti-2626	47	43	wild	wild	ADJ
dti-2626	47	44	-	-	PUNCT
dti-2626	47	45	type	type	NOUN
dti-2626	47	46	cancers	cancer	NOUN
dti-2626	47	47	(	(	PUNCT
dti-2626	47	48	13,14	13,14	NUM
dti-2626	47	49	)	)	PUNCT
dti-2626	47	50	.	.	PUNCT
dti-2626	48	1	however	however	ADV
dti-2626	48	2	,	,	PUNCT
dti-2626	48	3	no	no	DET
dti-2626	48	4	randomized	randomized	ADJ
dti-2626	48	5	comparisons	comparison	NOUN
dti-2626	48	6	of	of	ADP
dti-2626	48	7	immunotherapy	immunotherapy	NOUN
dti-2626	48	8	,	,	PUNCT
dti-2626	48	9	either	either	CCONJ
dti-2626	48	10	with	with	ADP
dti-2626	48	11	or	or	CCONJ
dti-2626	48	12	without	without	ADP
dti-2626	48	13	chemotherapy	chemotherapy	NOUN
dti-2626	48	14	,	,	PUNCT
dti-2626	48	15	vs.	vs.	CCONJ
dti-2626	48	16	met	meet	VERB
dti-2626	48	17	inhibitors	inhibitor	NOUN
dti-2626	48	18	are	be	AUX
dti-2626	48	19	available	available	ADJ
dti-2626	48	20	for	for	ADP
dti-2626	48	21	patients	patient	NOUN
dti-2626	48	22	with	with	ADP
dti-2626	48	23	metex14	metex14	NOUN
dti-2626	48	24	mutant	mutant	NOUN
dti-2626	48	25	metastatic	metastatic	ADJ
dti-2626	48	26	nsclc	nsclc	NOUN
dti-2626	48	27	as	as	ADP
dti-2626	48	28	front	front	ADJ
dti-2626	48	29	-	-	PUNCT
dti-2626	48	30	line	line	NOUN
dti-2626	48	31	treatment	treatment	NOUN
dti-2626	48	32	.	.	PUNCT
dti-2626	49	1	of	of	ADP
dti-2626	49	2	note	note	NOUN
dti-2626	49	3	,	,	PUNCT
dti-2626	49	4	metex14	metex14	NOUN
dti-2626	49	5	-	-	PUNCT
dti-2626	49	6	mutated	mutate	VERB
dti-2626	49	7	nsclc	nsclc	NOUN
dti-2626	49	8	is	be	AUX
dti-2626	49	9	mainly	mainly	ADV
dti-2626	49	10	found	find	VERB
dti-2626	49	11	in	in	ADP
dti-2626	49	12	elderly	elderly	ADJ
dti-2626	49	13	subjects	subject	NOUN
dti-2626	49	14	(	(	PUNCT
dti-2626	49	15	15	15	NUM
dti-2626	49	16	)	)	PUNCT
dti-2626	49	17	.	.	PUNCT
dti-2626	50	1	elderly	elderly	ADJ
dti-2626	50	2	patients	patient	NOUN
dti-2626	50	3	were	be	AUX
dti-2626	50	4	generally	generally	ADV
dti-2626	50	5	underrepresented	underrepresented	ADJ
dti-2626	50	6	in	in	ADP
dti-2626	50	7	clinical	clinical	ADJ
dti-2626	50	8	trials	trial	NOUN
dti-2626	50	9	investigating	investigate	VERB
dti-2626	50	10	immunotherapy	immunotherapy	NOUN
dti-2626	50	11	with	with	ADP
dti-2626	50	12	or	or	CCONJ
dti-2626	50	13	without	without	ADP
dti-2626	50	14	chemotherapy	chemotherapy	NOUN
dti-2626	50	15	in	in	ADP
dti-2626	50	16	nsclc	nsclc	NOUN
dti-2626	50	17	;	;	PUNCT
dti-2626	50	18	therefore	therefore	ADV
dti-2626	50	19	,	,	PUNCT
dti-2626	50	20	the	the	DET
dti-2626	50	21	benefit	benefit	NOUN
dti-2626	50	22	/	/	SYM
dti-2626	50	23	risk	risk	NOUN
dti-2626	50	24	balance	balance	NOUN
dti-2626	50	25	of	of	ADP
dti-2626	50	26	these	these	DET
dti-2626	50	27	regimens	regimen	NOUN
dti-2626	50	28	should	should	AUX
dti-2626	50	29	be	be	AUX
dti-2626	50	30	carefully	carefully	ADV
dti-2626	50	31	assessed	assess	VERB
dti-2626	50	32	individually	individually	ADV
dti-2626	50	33	when	when	SCONJ
dti-2626	50	34	treating	treat	VERB
dti-2626	50	35	older	old	ADJ
dti-2626	50	36	patients	patient	NOUN
dti-2626	50	37	in	in	ADP
dti-2626	50	38	daily	daily	ADJ
dti-2626	50	39	clinical	clinical	ADJ
dti-2626	50	40	practice	practice	NOUN
dti-2626	50	41	.	.	PUNCT
dti-2626	51	1	in	in	ADP
dti-2626	51	2	fact	fact	NOUN
dti-2626	51	3	,	,	PUNCT
dti-2626	51	4	a	a	DET
dti-2626	51	5	recent	recent	ADJ
dti-2626	51	6	pooled	pool	VERB
dti-2626	51	7	analysis	analysis	NOUN
dti-2626	51	8	showed	show	VERB
dti-2626	51	9	that	that	SCONJ
dti-2626	51	10	addition	addition	NOUN
dti-2626	51	11	of	of	ADP
dti-2626	51	12	chemotherapy	chemotherapy	NOUN
dti-2626	51	13	to	to	ADP
dti-2626	51	14	immunotherapy	immunotherapy	NOUN
dti-2626	51	15	in	in	ADP
dti-2626	51	16	patients	patient	NOUN
dti-2626	51	17	with	with	ADP
dti-2626	51	18	pd	pd	PROPN
dti-2626	51	19	-	-	PROPN
dti-2626	51	20	l1	l1	PROPN
dti-2626	51	21	≥50	≥50	NUM
dti-2626	51	22	%	%	NOUN
dti-2626	51	23	older	old	ADJ
dti-2626	51	24	than	than	ADP
dti-2626	51	25	75	75	NUM
dti-2626	51	26	years	year	NOUN
dti-2626	51	27	was	be	AUX
dti-2626	51	28	not	not	PART
dti-2626	51	29	beneficial	beneficial	ADJ
dti-2626	51	30	(	(	PUNCT
dti-2626	51	31	16	16	NUM
dti-2626	51	32	)	)	PUNCT
dti-2626	51	33	.	.	PUNCT
dti-2626	52	1	chemotherapy	chemotherapy	NOUN
dti-2626	52	2	alone	alone	ADV
dti-2626	52	3	may	may	AUX
dti-2626	52	4	represent	represent	VERB
dti-2626	52	5	another	another	DET
dti-2626	52	6	option	option	NOUN
dti-2626	52	7	for	for	ADP
dti-2626	52	8	elderly	elderly	ADJ
dti-2626	52	9	patients	patient	NOUN
dti-2626	52	10	with	with	ADP
dti-2626	52	11	advanced	advanced	ADJ
dti-2626	52	12	nsclc	nsclc	NOUN
dti-2626	52	13	.	.	PUNCT
dti-2626	53	1	however	however	ADV
dti-2626	53	2	,	,	PUNCT
dti-2626	53	3	a	a	DET
dti-2626	53	4	joint	joint	ADJ
dti-2626	53	5	analysis	analysis	NOUN
dti-2626	53	6	of	of	ADP
dti-2626	53	7	two	two	NUM
dti-2626	53	8	randomized	randomized	ADJ
dti-2626	53	9	trials	trial	NOUN
dti-2626	53	10	on	on	ADP
dti-2626	53	11	nsclc	nsclc	NOUN
dti-2626	53	12	older	old	ADJ
dti-2626	53	13	than	than	ADP
dti-2626	53	14	70	70	NUM
dti-2626	53	15	years	year	NOUN
dti-2626	53	16	reported	report	VERB
dti-2626	53	17	limited	limited	ADJ
dti-2626	53	18	activity	activity	NOUN
dti-2626	53	19	of	of	ADP
dti-2626	53	20	chemotherapy	chemotherapy	NOUN
dti-2626	53	21	in	in	ADP
dti-2626	53	22	this	this	DET
dti-2626	53	23	population	population	NOUN
dti-2626	53	24	,	,	PUNCT
dti-2626	53	25	with	with	ADP
dti-2626	53	26	a	a	DET
dti-2626	53	27	median	median	ADJ
dti-2626	53	28	progression	progression	NOUN
dti-2626	53	29	-	-	PUNCT
dti-2626	53	30	free	free	ADJ
dti-2626	53	31	survival	survival	NOUN
dti-2626	53	32	(	(	PUNCT
dti-2626	53	33	pfs	pfs	PROPN
dti-2626	53	34	)	)	PUNCT
dti-2626	53	35	of	of	ADP
dti-2626	53	36	3	3	NUM
dti-2626	53	37	months	month	NOUN
dti-2626	53	38	for	for	ADP
dti-2626	53	39	single	single	ADJ
dti-2626	53	40	-	-	PUNCT
dti-2626	53	41	agent	agent	NOUN
dti-2626	53	42	chemotherapy	chemotherapy	NOUN
dti-2626	53	43	(	(	PUNCT
dti-2626	53	44	either	either	CCONJ
dti-2626	53	45	gemcitabine	gemcitabine	NOUN
dti-2626	53	46	or	or	CCONJ
dti-2626	53	47	pemetrexed	pemetrexe	VERB
dti-2626	53	48	)	)	PUNCT
dti-2626	53	49	and	and	CCONJ
dti-2626	53	50	4.6	4.6	NUM
dti-2626	53	51	months	month	NOUN
dti-2626	53	52	with	with	ADP
dti-2626	53	53	the	the	DET
dti-2626	53	54	addition	addition	NOUN
dti-2626	53	55	of	of	ADP
dti-2626	53	56	cisplatin	cisplatin	NOUN
dti-2626	53	57	.	.	PUNCT
dti-2626	54	1	interestingly	interestingly	ADV
dti-2626	54	2	,	,	PUNCT
dti-2626	54	3	in	in	ADP
dti-2626	54	4	this	this	DET
dti-2626	54	5	joint	joint	ADJ
dti-2626	54	6	analysis	analysis	NOUN
dti-2626	54	7	the	the	DET
dti-2626	54	8	addition	addition	NOUN
dti-2626	54	9	of	of	ADP
dti-2626	54	10	cisplatin	cisplatin	NOUN
dti-2626	54	11	to	to	ADP
dti-2626	54	12	single	single	ADJ
dti-2626	54	13	-	-	PUNCT
dti-2626	54	14	agent	agent	NOUN
dti-2626	54	15	chemotherapy	chemotherapy	NOUN
dti-2626	54	16	did	do	AUX
dti-2626	54	17	not	not	PART
dti-2626	54	18	significantly	significantly	ADV
dti-2626	54	19	prolong	prolong	VERB
dti-2626	54	20	os	os	NOUN
dti-2626	54	21	(	(	PUNCT
dti-2626	54	22	17	17	NUM
dti-2626	54	23	)	)	PUNCT
dti-2626	54	24	.	.	PUNCT
dti-2626	55	1	thus	thus	ADV
dti-2626	55	2	,	,	PUNCT
dti-2626	55	3	the	the	DET
dti-2626	55	4	use	use	NOUN
dti-2626	55	5	of	of	ADP
dti-2626	55	6	platinum	platinum	NOUN
dti-2626	55	7	-	-	PUNCT
dti-2626	55	8	based	base	VERB
dti-2626	55	9	chemotherapy	chemotherapy	NOUN
dti-2626	55	10	,	,	PUNCT
dti-2626	55	11	with	with	ADP
dti-2626	55	12	or	or	CCONJ
dti-2626	55	13	without	without	ADP
dti-2626	55	14	immunotherapy	immunotherapy	NOUN
dti-2626	55	15	,	,	PUNCT
dti-2626	55	16	may	may	AUX
dti-2626	55	17	be	be	AUX
dti-2626	55	18	questionable	questionable	ADJ
dti-2626	55	19	in	in	ADP
dti-2626	55	20	elderly	elderly	ADJ
dti-2626	55	21	patients	patient	NOUN
dti-2626	55	22	.	.	PUNCT
dti-2626	56	1	in	in	ADP
dti-2626	56	2	clinical	clinical	ADJ
dti-2626	56	3	trials	trial	NOUN
dti-2626	56	4	,	,	PUNCT
dti-2626	56	5	selective	selective	ADJ
dti-2626	56	6	met	meet	VERB
dti-2626	56	7	inhibitors	inhibitor	NOUN
dti-2626	56	8	including	include	VERB
dti-2626	56	9	tepotinib	tepotinib	NOUN
dti-2626	56	10	,	,	PUNCT
dti-2626	56	11	capmatinib	capmatinib	NOUN
dti-2626	56	12	and	and	CCONJ
dti-2626	56	13	savolitinib	savolitinib	NOUN
dti-2626	56	14	have	have	AUX
dti-2626	56	15	recently	recently	ADV
dti-2626	56	16	shown	show	VERB
dti-2626	56	17	meaningful	meaningful	ADJ
dti-2626	56	18	activity	activity	NOUN
dti-2626	56	19	against	against	ADP
dti-2626	56	20	metex14	metex14	NOUN
dti-2626	56	21	-	-	PUNCT
dti-2626	56	22	mutated	mutate	VERB
dti-2626	56	23	nsclc	nsclc	NOUN
dti-2626	56	24	.	.	PUNCT
dti-2626	57	1	particularly	particularly	ADV
dti-2626	57	2	,	,	PUNCT
dti-2626	57	3	in	in	ADP
dti-2626	57	4	the	the	DET
dti-2626	57	5	phase	phase	NOUN
dti-2626	57	6	ii	ii	PROPN
dti-2626	57	7	vision	vision	NOUN
dti-2626	57	8	study	study	NOUN
dti-2626	57	9	,	,	PUNCT
dti-2626	57	10	among	among	ADP
dti-2626	57	11	152	152	NUM
dti-2626	57	12	metex14	metex14	NOUN
dti-2626	57	13	-	-	PUNCT
dti-2626	57	14	mutated	mutate	VERB
dti-2626	57	15	nsclc	nsclc	NOUN
dti-2626	57	16	patients	patient	NOUN
dti-2626	57	17	treated	treat	VERB
dti-2626	57	18	with	with	ADP
dti-2626	57	19	tepotinib	tepotinib	NOUN
dti-2626	57	20	,	,	PUNCT
dti-2626	57	21	the	the	DET
dti-2626	57	22	response	response	NOUN
dti-2626	57	23	rate	rate	NOUN
dti-2626	57	24	by	by	ADP
dti-2626	57	25	inde	inde	PROPN
dti-2626	57	26	pendent	pendent	PROPN
dti-2626	57	27	review	review	NOUN
dti-2626	57	28	was	be	AUX
dti-2626	57	29	46	46	NUM
dti-2626	57	30	%	%	NOUN
dti-2626	57	31	,	,	PUNCT
dti-2626	57	32	and	and	CCONJ
dti-2626	57	33	median	median	ADJ
dti-2626	57	34	pfs	pfs	PROPN
dti-2626	57	35	was	be	AUX
dti-2626	57	36	8.5	8.5	NUM
dti-2626	57	37	months	month	NOUN
dti-2626	57	38	.	.	PUNCT
dti-2626	58	1	this	this	DET
dti-2626	58	2	trial	trial	NOUN
dti-2626	58	3	enrolled	enrol	VERB
dti-2626	58	4	both	both	DET
dti-2626	58	5	treatment	treatment	NOUN
dti-2626	58	6	-	-	PUNCT
dti-2626	58	7	naive	naive	ADJ
dti-2626	58	8	and	and	CCONJ
dti-2626	58	9	preatreted	preatrete	VERB
dti-2626	58	10	patients	patient	NOUN
dti-2626	58	11	.	.	PUNCT
dti-2626	59	1	interestingly	interestingly	ADV
dti-2626	59	2	,	,	PUNCT
dti-2626	59	3	in	in	ADP
dti-2626	59	4	treatment	treatment	NOUN
dti-2626	59	5	-	-	PUNCT
dti-2626	59	6	naive	naive	ADJ
dti-2626	59	7	patients	patient	NOUN
dti-2626	59	8	(	(	PUNCT
dti-2626	59	9	n	n	NOUN
dti-2626	59	10	=	=	SYM
dti-2626	59	11	164	164	NUM
dti-2626	59	12	)	)	PUNCT
dti-2626	59	13	,	,	PUNCT
dti-2626	59	14	objective	objective	ADJ
dti-2626	59	15	response	response	NOUN
dti-2626	59	16	rate	rate	NOUN
dti-2626	59	17	(	(	PUNCT
dti-2626	59	18	orr	orr	PROPN
dti-2626	59	19	)	)	PUNCT
dti-2626	59	20	was	be	AUX
dti-2626	59	21	57.3	57.3	NUM
dti-2626	59	22	%	%	NOUN
dti-2626	59	23	and	and	CCONJ
dti-2626	59	24	median	median	ADJ
dti-2626	59	25	dor	dor	PROPN
dti-2626	59	26	was	be	AUX
dti-2626	59	27	46.4	46.4	NUM
dti-2626	59	28	months	month	NOUN
dti-2626	59	29	,	,	PUNCT
dti-2626	59	30	whereas	whereas	SCONJ
dti-2626	59	31	among	among	ADP
dti-2626	59	32	pretreated	pretreated	ADJ
dti-2626	59	33	patients	patient	NOUN
dti-2626	59	34	,	,	PUNCT
dti-2626	59	35	orr	orr	PROPN
dti-2626	59	36	was	be	AUX
dti-2626	59	37	45.0	45.0	NUM
dti-2626	59	38	%	%	NOUN
dti-2626	59	39	and	and	CCONJ
dti-2626	59	40	median	median	ADJ
dti-2626	59	41	dor	dor	PROPN
dti-2626	59	42	was	be	AUX
dti-2626	59	43	12.6	12.6	NUM
dti-2626	59	44	months	month	NOUN
dti-2626	59	45	,	,	PUNCT
dti-2626	59	46	suggesting	suggest	VERB
dti-2626	59	47	that	that	SCONJ
dti-2626	59	48	tepotinib	tepotinib	NOUN
dti-2626	59	49	might	might	AUX
dti-2626	59	50	be	be	AUX
dti-2626	59	51	more	more	ADV
dti-2626	59	52	beneficial	beneficial	ADJ
dti-2626	59	53	as	as	ADP
dti-2626	59	54	front	front	ADJ
dti-2626	59	55	-	-	PUNCT
dti-2626	59	56	line	line	NOUN
dti-2626	59	57	treatment	treatment	NOUN
dti-2626	59	58	.	.	PUNCT
dti-2626	60	1	in	in	ADP
dti-2626	60	2	this	this	DET
dti-2626	60	3	study	study	NOUN
dti-2626	60	4	,	,	PUNCT
dti-2626	60	5	the	the	DET
dti-2626	60	6	toxicity	toxicity	NOUN
dti-2626	60	7	profile	profile	NOUN
dti-2626	60	8	of	of	ADP
dti-2626	60	9	tepotinib	tepotinib	NOUN
dti-2626	60	10	was	be	AUX
dti-2626	60	11	acceptable	acceptable	ADJ
dti-2626	60	12	,	,	PUNCT
dti-2626	60	13	with	with	ADP
dti-2626	60	14	peripheral	peripheral	ADJ
dti-2626	60	15	edema	edema	NOUN
dti-2626	60	16	reported	report	VERB
dti-2626	60	17	as	as	ADP
dti-2626	60	18	main	main	ADJ
dti-2626	60	19	grade	grade	NOUN
dti-2626	60	20	3	3	NUM
dti-2626	60	21	toxicity	toxicity	NOUN
dti-2626	60	22	.	.	PUNCT
dti-2626	61	1	in	in	ADP
dti-2626	61	2	this	this	DET
dti-2626	61	3	study	study	NOUN
dti-2626	61	4	,	,	PUNCT
dti-2626	61	5	43	43	NUM
dti-2626	61	6	%	%	NOUN
dti-2626	61	7	of	of	ADP
dti-2626	61	8	patients	patient	NOUN
dti-2626	61	9	received	receive	VERB
dti-2626	61	10	tepotinib	tepotinib	NOUN
dti-2626	61	11	as	as	ADP
dti-2626	61	12	the	the	DET
dti-2626	61	13	first	first	ADJ
dti-2626	61	14	-	-	PUNCT
dti-2626	61	15	line	line	NOUN
dti-2626	61	16	treatment	treatment	NOUN
dti-2626	61	17	(	(	PUNCT
dti-2626	61	18	2,3	2,3	NUM
dti-2626	61	19	)	)	PUNCT
dti-2626	61	20	.	.	PUNCT
dti-2626	62	1	in	in	ADP
dti-2626	62	2	the	the	DET
dti-2626	62	3	phase	phase	NOUN
dti-2626	62	4	ii	ii	NOUN
dti-2626	62	5	geometry	geometry	NOUN
dti-2626	62	6	mono-1	mono-1	NOUN
dti-2626	62	7	study	study	NOUN
dti-2626	62	8	,	,	PUNCT
dti-2626	62	9	among	among	ADP
dti-2626	62	10	97	97	NUM
dti-2626	62	11	metex14	metex14	NOUN
dti-2626	62	12	-	-	PUNCT
dti-2626	62	13	mutated	mutate	VERB
dti-2626	62	14	nsclc	nsclc	NOUN
dti-2626	62	15	patients	patient	NOUN
dti-2626	62	16	treated	treat	VERB
dti-2626	62	17	with	with	ADP
dti-2626	62	18	capmatinib	capmatinib	NOUN
dti-2626	62	19	,	,	PUNCT
dti-2626	62	20	the	the	DET
dti-2626	62	21	orr	orr	PROPN
dti-2626	62	22	was	be	AUX
dti-2626	62	23	observed	observe	VERB
dti-2626	62	24	in	in	ADP
dti-2626	62	25	41	41	NUM
dti-2626	62	26	%	%	NOUN
dti-2626	62	27	of	of	ADP
dti-2626	62	28	69	69	NUM
dti-2626	62	29	patients	patient	NOUN
dti-2626	62	30	who	who	PRON
dti-2626	62	31	had	have	AUX
dti-2626	62	32	previously	previously	ADV
dti-2626	62	33	received	receive	VERB
dti-2626	62	34	one	one	NUM
dti-2626	62	35	or	or	CCONJ
dti-2626	62	36	two	two	NUM
dti-2626	62	37	lines	line	NOUN
dti-2626	62	38	of	of	ADP
dti-2626	62	39	therapy	therapy	NOUN
dti-2626	62	40	and	and	CCONJ
dti-2626	62	41	in	in	ADP
dti-2626	62	42	68	68	NUM
dti-2626	62	43	%	%	NOUN
dti-2626	62	44	of	of	ADP
dti-2626	62	45	28	28	NUM
dti-2626	62	46	previously	previously	ADV
dti-2626	62	47	untreated	untreated	ADJ
dti-2626	62	48	patients	patient	NOUN
dti-2626	62	49	;	;	PUNCT
dti-2626	62	50	the	the	DET
dti-2626	62	51	median	median	ADJ
dti-2626	62	52	dor	dor	PROPN
dti-2626	62	53	was	be	AUX
dti-2626	62	54	9.7	9.7	NUM
dti-2626	62	55	months	month	NOUN
dti-2626	62	56	and	and	CCONJ
dti-2626	62	57	12.6	12.6	NUM
dti-2626	62	58	months	month	NOUN
dti-2626	62	59	,	,	PUNCT
dti-2626	62	60	respectively	respectively	ADV
dti-2626	62	61	(	(	PUNCT
dti-2626	62	62	18	18	NUM
dti-2626	62	63	)	)	PUNCT
dti-2626	62	64	.	.	PUNCT
dti-2626	63	1	a	a	DET
dti-2626	63	2	chinese	chinese	ADJ
dti-2626	63	3	phase	phase	NOUN
dti-2626	63	4	ii	ii	PROPN
dti-2626	63	5	study	study	NOUN
dti-2626	63	6	evaluated	evaluate	VERB
dti-2626	63	7	savolitinib	savolitinib	NOUN
dti-2626	63	8	in	in	ADP
dti-2626	63	9	70	70	NUM
dti-2626	63	10	patients	patient	NOUN
dti-2626	63	11	with	with	ADP
dti-2626	63	12	metex14	metex14	NOUN
dti-2626	63	13	-	-	PUNCT
dti-2626	63	14	mutated	mutate	VERB
dti-2626	63	15	nsclc	nsclc	NOUN
dti-2626	63	16	after	after	ADP
dti-2626	63	17	≥1	≥1	NUM
dti-2626	63	18	line	line	NOUN
dti-2626	63	19	of	of	ADP
dti-2626	63	20	standard	standard	ADJ
dti-2626	63	21	treatment	treatment	NOUN
dti-2626	63	22	or	or	CCONJ
dti-2626	63	23	deemed	deem	VERB
dti-2626	63	24	unsuitable	unsuitable	ADJ
dti-2626	63	25	for	for	ADP
dti-2626	63	26	standard	standard	ADJ
dti-2626	63	27	treatment	treatment	NOUN
dti-2626	63	28	,	,	PUNCT
dti-2626	63	29	reporting	report	VERB
dti-2626	63	30	an	an	DET
dti-2626	63	31	orr	orr	NOUN
dti-2626	63	32	of	of	ADP
dti-2626	63	33	42.9	42.9	NUM
dti-2626	63	34	%	%	NOUN
dti-2626	63	35	(	(	PUNCT
dti-2626	63	36	19	19	NUM
dti-2626	63	37	)	)	PUNCT
dti-2626	63	38	.	.	PUNCT
dti-2626	64	1	our	our	PRON
dti-2626	64	2	patient	patient	NOUN
dti-2626	64	3	achieved	achieve	VERB
dti-2626	64	4	a	a	DET
dti-2626	64	5	partial	partial	ADJ
dti-2626	64	6	response	response	NOUN
dti-2626	64	7	to	to	ADP
dti-2626	64	8	tepotinib	tepotinib	NOUN
dti-2626	64	9	,	,	PUNCT
dti-2626	64	10	with	with	ADP
dti-2626	64	11	a	a	DET
dti-2626	64	12	pfs	pfs	NOUN
dti-2626	64	13	of	of	ADP
dti-2626	64	14	31	31	NUM
dti-2626	64	15	+	+	NUM
dti-2626	64	16	months	month	NOUN
dti-2626	64	17	and	and	CCONJ
dti-2626	64	18	dor	dor	NOUN
dti-2626	64	19	of	of	ADP
dti-2626	64	20	28	28	NUM
dti-2626	64	21	+	+	NUM
dti-2626	64	22	months	month	NOUN
dti-2626	64	23	,	,	PUNCT
dti-2626	64	24	that	that	PRON
dti-2626	64	25	is	be	AUX
dti-2626	64	26	consistent	consistent	ADJ
dti-2626	64	27	with	with	ADP
dti-2626	64	28	data	datum	NOUN
dti-2626	64	29	from	from	ADP
dti-2626	64	30	vision	vision	NOUN
dti-2626	64	31	trial	trial	NOUN
dti-2626	64	32	and	and	CCONJ
dti-2626	64	33	compares	compare	VERB
dti-2626	64	34	favorably	favorably	ADV
dti-2626	64	35	with	with	ADP
dti-2626	64	36	data	datum	NOUN
dti-2626	64	37	of	of	ADP
dti-2626	64	38	first	first	ADJ
dti-2626	64	39	-	-	PUNCT
dti-2626	64	40	line	line	NOUN
dti-2626	64	41	immunotherapy	immunotherapy	NOUN
dti-2626	64	42	or	or	CCONJ
dti-2626	64	43	chemotherapy	chemotherapy	NOUN
dti-2626	64	44	.	.	PUNCT
dti-2626	65	1	based	base	VERB
dti-2626	65	2	on	on	ADP
dti-2626	65	3	this	this	DET
dti-2626	65	4	observation	observation	NOUN
dti-2626	65	5	,	,	PUNCT
dti-2626	65	6	we	we	PRON
dti-2626	65	7	believe	believe	VERB
dti-2626	65	8	that	that	PRON
dti-2626	65	9	met	meet	VERB
dti-2626	65	10	inhibitors	inhibitor	NOUN
dti-2626	65	11	represent	represent	VERB
dti-2626	65	12	an	an	DET
dti-2626	65	13	effective	effective	ADJ
dti-2626	65	14	and	and	CCONJ
dti-2626	65	15	well	well	ADV
dti-2626	65	16	-	-	PUNCT
dti-2626	65	17	tolerated	tolerate	VERB
dti-2626	65	18	therapy	therapy	NOUN
dti-2626	65	19	for	for	ADP
dti-2626	65	20	metastatic	metastatic	ADJ
dti-2626	65	21	,	,	PUNCT
dti-2626	65	22	metex14	metex14	NOUN
dti-2626	65	23	mutant	mutant	ADJ
dti-2626	65	24	nsclc	nsclc	NOUN
dti-2626	65	25	in	in	ADP
dti-2626	65	26	the	the	DET
dti-2626	65	27	first	first	ADJ
dti-2626	65	28	-	-	PUNCT
dti-2626	65	29	line	line	NOUN
dti-2626	65	30	setting	setting	NOUN
dti-2626	65	31	.	.	PUNCT
dti-2626	66	1	unfortunately	unfortunately	ADV
dti-2626	66	2	,	,	PUNCT
dti-2626	66	3	the	the	DET
dti-2626	66	4	ema	ema	PROPN
dti-2626	66	5	approval	approval	NOUN
dti-2626	66	6	of	of	ADP
dti-2626	66	7	met	meet	VERB
dti-2626	66	8	inhibitors	inhibitor	NOUN
dti-2626	66	9	only	only	ADV
dti-2626	66	10	for	for	ADP
dti-2626	66	11	patients	patient	NOUN
dti-2626	66	12	with	with	ADP
dti-2626	66	13	progressive	progressive	ADJ
dti-2626	66	14	disease	disease	NOUN
dti-2626	66	15	after	after	SCONJ
dti-2626	66	16	chemotherapy	chemotherapy	NOUN
dti-2626	66	17	and/or	and/or	CCONJ
dti-2626	66	18	immunotherapy	immunotherapy	NOUN
dti-2626	66	19	is	be	AUX
dti-2626	66	20	likely	likely	ADJ
dti-2626	66	21	to	to	PART
dti-2626	66	22	limit	limit	VERB
dti-2626	66	23	across	across	ADP
dti-2626	66	24	europe	europe	PROPN
dti-2626	66	25	the	the	DET
dti-2626	66	26	access	access	NOUN
dti-2626	66	27	to	to	ADP
dti-2626	66	28	treatment	treatment	NOUN
dti-2626	66	29	for	for	ADP
dti-2626	66	30	very	very	ADV
dti-2626	66	31	elderly	elderly	ADJ
dti-2626	66	32	patients	patient	NOUN
dti-2626	66	33	unfit	unfit	ADJ
dti-2626	66	34	to	to	PART
dti-2626	66	35	receive	receive	VERB
dti-2626	66	36	first	first	ADJ
dti-2626	66	37	-	-	PUNCT
dti-2626	66	38	line	line	NOUN
dti-2626	66	39	chemotherapy	chemotherapy	NOUN
dti-2626	66	40	and/or	and/or	CCONJ
dti-2626	66	41	immunotherapy	immunotherapy	NOUN
dti-2626	66	42	before	before	ADV
dti-2626	66	43	met	meet	VERB
dti-2626	66	44	inhibitors	inhibitor	NOUN
dti-2626	66	45	.	.	PUNCT
dti-2626	67	1	acknowledgments	acknowledgment	NOUN
dti-2626	67	2	medical	medical	ADJ
dti-2626	67	3	writing	writing	NOUN
dti-2626	67	4	services	service	NOUN
dti-2626	67	5	were	be	AUX
dti-2626	67	6	provided	provide	VERB
dti-2626	67	7	by	by	ADP
dti-2626	67	8	laura	laura	PROPN
dti-2626	67	9	brogelli	brogelli	PROPN
dti-2626	67	10	,	,	PUNCT
dti-2626	67	11	valentina	valentina	PROPN
dti-2626	67	12	attanasio	attanasio	NOUN
dti-2626	67	13	,	,	PUNCT
dti-2626	67	14	and	and	CCONJ
dti-2626	67	15	aashni	aashni	ADP
dti-2626	67	16	shah	shah	NOUN
dti-2626	67	17	(	(	PUNCT
dti-2626	67	18	polistudium	polistudium	NOUN
dti-2626	67	19	srl	srl	PROPN
dti-2626	67	20	,	,	PUNCT
dti-2626	67	21	milan	milan	PROPN
dti-2626	67	22	,	,	PUNCT
dti-2626	67	23	italy	italy	PROPN
dti-2626	67	24	)	)	PUNCT
dti-2626	67	25	.	.	PUNCT
dti-2626	68	1	disclosures	disclosure	VERB
dti-2626	68	2	conflict	conflict	NOUN
dti-2626	68	3	of	of	ADP
dti-2626	68	4	interest	interest	NOUN
dti-2626	68	5	:	:	PUNCT
dti-2626	68	6	the	the	DET
dti-2626	68	7	authors	author	NOUN
dti-2626	68	8	declare	declare	VERB
dti-2626	68	9	no	no	DET
dti-2626	68	10	conflict	conflict	NOUN
dti-2626	68	11	of	of	ADP
dti-2626	68	12	interest	interest	NOUN
dti-2626	68	13	.	.	PUNCT
dti-2626	69	1	financial	financial	ADJ
dti-2626	69	2	support	support	NOUN
dti-2626	69	3	:	:	PUNCT
dti-2626	69	4	the	the	DET
dti-2626	69	5	development	development	NOUN
dti-2626	69	6	of	of	ADP
dti-2626	69	7	this	this	DET
dti-2626	69	8	publication	publication	NOUN
dti-2626	69	9	was	be	AUX
dti-2626	69	10	financially	financially	ADV
dti-2626	69	11	supported	support	VERB
dti-2626	69	12	by	by	ADP
dti-2626	69	13	merck	merck	PROPN
dti-2626	69	14	serono	serono	PROPN
dti-2626	69	15	s.p.a	s.p.a	PROPN
dti-2626	69	16	.	.	PROPN
dti-2626	69	17	,	,	PUNCT
dti-2626	69	18	rome	rome	PROPN
dti-2626	69	19	,	,	PUNCT
dti-2626	69	20	italy	italy	PROPN
dti-2626	69	21	,	,	PUNCT
dti-2626	69	22	an	an	DET
dti-2626	69	23	affiliate	affiliate	NOUN
dti-2626	69	24	of	of	ADP
dti-2626	69	25	merck	merck	PROPN
dti-2626	69	26	kgaa	kgaa	PROPN
dti-2626	69	27	,	,	PUNCT
dti-2626	69	28	darmstadt	darmstadt	PROPN
dti-2626	69	29	,	,	PUNCT
dti-2626	69	30	germany	germany	PROPN
dti-2626	69	31	through	through	ADP
dti-2626	69	32	an	an	DET
dti-2626	69	33	independent	independent	ADJ
dti-2626	69	34	medical	medical	ADJ
dti-2626	69	35	writing	writing	NOUN
dti-2626	69	36	grant	grant	NOUN
dti-2626	69	37	.	.	PUNCT
dti-2626	70	1	the	the	DET
dti-2626	70	2	views	view	NOUN
dti-2626	70	3	and	and	CCONJ
dti-2626	70	4	opinions	opinion	NOUN
dti-2626	70	5	described	describe	VERB
dti-2626	70	6	in	in	ADP
dti-2626	70	7	this	this	DET
dti-2626	70	8	publication	publication	NOUN
dti-2626	70	9	do	do	AUX
dti-2626	70	10	not	not	PART
dti-2626	70	11	necessarily	necessarily	ADV
dti-2626	70	12	reflect	reflect	VERB
dti-2626	70	13	those	those	PRON
dti-2626	70	14	of	of	ADP
dti-2626	70	15	the	the	DET
dti-2626	70	16	grantor	grantor	NOUN
dti-2626	70	17	.	.	PUNCT
dti-2626	71	1	author	author	NOUN
dti-2626	71	2	contributions	contribution	NOUN
dti-2626	71	3	:	:	PUNCT
dti-2626	71	4	collection	collection	NOUN
dti-2626	71	5	and	and	CCONJ
dti-2626	71	6	interpretation	interpretation	NOUN
dti-2626	71	7	of	of	ADP
dti-2626	71	8	data	datum	NOUN
dti-2626	71	9	:	:	PUNCT
dti-2626	71	10	all	all	DET
dti-2626	71	11	authors	author	NOUN
dti-2626	71	12	;	;	PUNCT
dti-2626	71	13	manuscript	manuscript	NOUN
dti-2626	71	14	drafting	drafting	NOUN
dti-2626	71	15	:	:	PUNCT
dti-2626	71	16	ai	ai	VERB
dti-2626	71	17	;	;	PUNCT
dti-2626	71	18	approval	approval	NOUN
dti-2626	71	19	to	to	PART
dti-2626	71	20	submit	submit	VERB
dti-2626	71	21	:	:	PUNCT
dti-2626	71	22	all	all	DET
dti-2626	71	23	authors	author	NOUN
dti-2626	71	24	.	.	PUNCT
dti-2626	72	1	data	datum	NOUN
dti-2626	72	2	availability	availability	NOUN
dti-2626	72	3	statement	statement	NOUN
dti-2626	72	4	:	:	PUNCT
dti-2626	73	1	data	datum	NOUN
dti-2626	73	2	described	describe	VERB
dti-2626	73	3	in	in	ADP
dti-2626	73	4	this	this	DET
dti-2626	73	5	article	article	NOUN
dti-2626	73	6	are	be	AUX
dti-2626	73	7	available	available	ADJ
dti-2626	73	8	from	from	ADP
dti-2626	73	9	the	the	DET
dti-2626	73	10	corresponding	corresponding	ADJ
dti-2626	73	11	author	author	NOUN
dti-2626	73	12	upon	upon	SCONJ
dti-2626	73	13	reasonable	reasonable	ADJ
dti-2626	73	14	request	request	NOUN
dti-2626	73	15	and	and	CCONJ
dti-2626	73	16	according	accord	VERB
dti-2626	73	17	to	to	ADP
dti-2626	73	18	ethical	ethical	ADJ
dti-2626	73	19	restrictions	restriction	NOUN
dti-2626	73	20	.	.	PUNCT
dti-2626	74	1	ethical	ethical	ADJ
dti-2626	74	2	approval	approval	NOUN
dti-2626	74	3	:	:	PUNCT
dti-2626	74	4	the	the	DET
dti-2626	74	5	patient	patient	NOUN
dti-2626	74	6	provided	provide	VERB
dti-2626	74	7	informed	informed	ADJ
dti-2626	74	8	written	write	VERB
dti-2626	74	9	consent	consent	NOUN
dti-2626	74	10	to	to	ADP
dti-2626	74	11	the	the	DET
dti-2626	74	12	publication	publication	NOUN
dti-2626	74	13	of	of	ADP
dti-2626	74	14	the	the	DET
dti-2626	74	15	anonymous	anonymous	ADJ
dti-2626	74	16	clinical	clinical	ADJ
dti-2626	74	17	description	description	NOUN
dti-2626	74	18	.	.	PUNCT
dti-2626	75	1	references	reference	NOUN
dti-2626	75	2	1	1	NUM
dti-2626	75	3	.	.	PUNCT
dti-2626	75	4	cancer	cancer	NOUN
dti-2626	75	5	genome	genome	NOUN
dti-2626	75	6	atlas	atlas	PROPN
dti-2626	75	7	research	research	PROPN
dti-2626	75	8	network	network	NOUN
dti-2626	75	9	.	.	PUNCT
dti-2626	76	1	comprehensive	comprehensive	ADJ
dti-2626	76	2	molecular	molecular	ADJ
dti-2626	76	3	profiling	profiling	NOUN
dti-2626	76	4	of	of	ADP
dti-2626	76	5	lung	lung	NOUN
dti-2626	76	6	adenocarcinoma	adenocarcinoma	NOUN
dti-2626	76	7	.	.	PUNCT
dti-2626	77	1	nature	nature	NOUN
dti-2626	77	2	.	.	PUNCT
dti-2626	78	1	2014;511	2014;511	NUM
dti-2626	78	2	(	(	PUNCT
dti-2626	78	3	7511):543	7511):543	NOUN
dti-2626	78	4	-	-	SYM
dti-2626	78	5	550	550	NUM
dti-2626	78	6	.	.	PUNCT
dti-2626	79	1	crossref	crossref	PROPN
dti-2626	79	2	pubmed	pubmed	PROPN
dti-2626	79	3	2	2	PROPN
dti-2626	79	4	.	.	PROPN
dti-2626	79	5	paik	paik	PROPN
dti-2626	79	6	pk	pk	PROPN
dti-2626	79	7	,	,	PUNCT
dti-2626	79	8	felip	felip	NOUN
dti-2626	79	9	e	e	NOUN
dti-2626	79	10	,	,	PUNCT
dti-2626	79	11	veillon	veillon	NOUN
dti-2626	79	12	r	r	NOUN
dti-2626	79	13	,	,	PUNCT
dti-2626	79	14	et	et	PROPN
dti-2626	79	15	al	al	PROPN
dti-2626	79	16	.	.	PROPN
dti-2626	79	17	tepotinib	tepotinib	NOUN
dti-2626	79	18	in	in	ADP
dti-2626	79	19	non	non	ADJ
dti-2626	79	20	-	-	ADJ
dti-2626	79	21	small	small	ADJ
dti-2626	79	22	-	-	PUNCT
dti-2626	79	23	cell	cell	NOUN
dti-2626	79	24	lung	lung	NOUN
dti-2626	79	25	cancer	cancer	NOUN
dti-2626	79	26	with	with	ADP
dti-2626	79	27	met	meet	VERB
dti-2626	79	28	exon	exon	NOUN
dti-2626	79	29	14	14	NUM
dti-2626	79	30	skipping	skip	VERB
dti-2626	79	31	mutations	mutation	NOUN
dti-2626	79	32	.	.	PUNCT
dti-2626	80	1	n	n	PRON
dti-2626	80	2	engl	engl	PROPN
dti-2626	80	3	j	j	PROPN
dti-2626	80	4	med	med	PROPN
dti-2626	80	5	.	.	PUNCT
dti-2626	81	1	2020;383(10):931	2020;383(10):931	NUM
dti-2626	81	2	-	-	SYM
dti-2626	81	3	943	943	NUM
dti-2626	81	4	.	.	PUNCT
dti-2626	82	1	crossref	crossref	PROPN
dti-2626	82	2	pubmed	pubmed	PROPN
dti-2626	82	3	3	3	PROPN
dti-2626	82	4	.	.	PUNCT
dti-2626	82	5	mazieres	mazieres	PROPN
dti-2626	82	6	j	j	PROPN
dti-2626	82	7	,	,	PUNCT
dti-2626	82	8	paik	paik	PROPN
dti-2626	82	9	pk	pk	NOUN
dti-2626	82	10	,	,	PUNCT
dti-2626	82	11	garassino	garassino	PROPN
dti-2626	82	12	mc	mc	PROPN
dti-2626	82	13	,	,	PUNCT
dti-2626	82	14	et	et	PROPN
dti-2626	82	15	al	al	PROPN
dti-2626	82	16	.	.	PROPN
dti-2626	83	1	tepotinib	tepotinib	PROPN
dti-2626	83	2	treatment	treatment	NOUN
dti-2626	83	3	in	in	ADP
dti-2626	83	4	patients	patient	NOUN
dti-2626	83	5	with	with	ADP
dti-2626	83	6	met	meet	VERB
dti-2626	83	7	exon	exon	PROPN
dti-2626	83	8	14	14	NUM
dti-2626	83	9	-	-	PUNCT
dti-2626	83	10	skipping	skip	VERB
dti-2626	83	11	non	non	ADJ
dti-2626	83	12	-	-	ADJ
dti-2626	83	13	small	small	ADJ
dti-2626	83	14	cell	cell	NOUN
dti-2626	83	15	lung	lung	NOUN
dti-2626	83	16	cancer	cancer	NOUN
dti-2626	83	17	:	:	PUNCT
dti-2626	83	18	long	long	ADJ
dti-2626	83	19	-	-	PUNCT
dti-2626	83	20	term	term	NOUN
dti-2626	83	21	follow	follow	NOUN
dti-2626	83	22	-	-	PUNCT
dti-2626	83	23	up	up	NOUN
dti-2626	83	24	of	of	ADP
dti-2626	83	25	the	the	DET
dti-2626	83	26	vision	vision	NOUN
dti-2626	83	27	phase	phase	NOUN
dti-2626	83	28	2	2	NUM
dti-2626	83	29	nonrandomized	nonrandomize	VERB
dti-2626	83	30	clinical	clinical	ADJ
dti-2626	83	31	trial	trial	NOUN
dti-2626	83	32	.	.	PUNCT
dti-2626	84	1	jama	jama	PROPN
dti-2626	84	2	oncol	oncol	ADJ
dti-2626	84	3	.	.	PUNCT
dti-2626	85	1	2023;e231962	2023;e231962	NUM
dti-2626	85	2	.	.	PUNCT
dti-2626	86	1	crossref	crossref	PROPN
dti-2626	86	2	pubmed	pubmed	PROPN
dti-2626	86	3	4	4	PROPN
dti-2626	86	4	.	.	PUNCT
dti-2626	86	5	european	european	PROPN
dti-2626	86	6	medicine	medicine	PROPN
dti-2626	86	7	agency	agency	PROPN
dti-2626	86	8	.	.	PUNCT
dti-2626	87	1	tepmetko	tepmetko	PROPN
dti-2626	87	2	.	.	PUNCT
dti-2626	88	1	online	online	PROPN
dti-2626	88	2	.	.	PUNCT
dti-2626	89	1	accessed	access	VERB
dti-2626	89	2	october	october	PROPN
dti-2626	89	3	2022	2022	NUM
dti-2626	89	4	.	.	PUNCT
dti-2626	90	1	5	5	NUM
dti-2626	90	2	.	.	X
dti-2626	90	3	u.s	u.s	PROPN
dti-2626	90	4	.	.	PROPN
dti-2626	90	5	food	food	PROPN
dti-2626	90	6	and	and	CCONJ
dti-2626	90	7	drug	drug	NOUN
dti-2626	90	8	administration	administration	NOUN
dti-2626	90	9	.	.	PUNCT
dti-2626	91	1	tepmekto	tepmekto	NOUN
dti-2626	91	2	2021	2021	NUM
dti-2626	91	3	.	.	PUNCT
dti-2626	92	1	online	online	PROPN
dti-2626	92	2	.	.	PUNCT
dti-2626	93	1	accessed	access	VERB
dti-2626	93	2	october	october	PROPN
dti-2626	93	3	2022	2022	NUM
dti-2626	93	4	.	.	PUNCT
dti-2626	94	1	6	6	NUM
dti-2626	94	2	.	.	X
dti-2626	94	3	reck	reck	PROPN
dti-2626	94	4	m	m	PROPN
dti-2626	94	5	,	,	PUNCT
dti-2626	94	6	remon	remon	PROPN
dti-2626	94	7	j	j	PROPN
dti-2626	94	8	,	,	PUNCT
dti-2626	94	9	hellmann	hellmann	PROPN
dti-2626	94	10	md	md	PROPN
dti-2626	94	11	.	.	PUNCT
dti-2626	95	1	first	first	ADJ
dti-2626	95	2	-	-	PUNCT
dti-2626	95	3	line	line	NOUN
dti-2626	95	4	immunotherapy	immunotherapy	NOUN
dti-2626	95	5	for	for	ADP
dti-2626	95	6	non	non	ADJ
dti-2626	95	7	-	-	ADJ
dti-2626	95	8	small	small	ADJ
dti-2626	95	9	-	-	PUNCT
dti-2626	95	10	cell	cell	NOUN
dti-2626	95	11	lung	lung	NOUN
dti-2626	95	12	cancer	cancer	NOUN
dti-2626	95	13	.	.	PUNCT
dti-2626	96	1	j	j	PROPN
dti-2626	96	2	clin	clin	PROPN
dti-2626	96	3	oncol	oncol	PROPN
dti-2626	96	4	.	.	PUNCT
dti-2626	97	1	2022;40(6):586	2022;40(6):586	NUM
dti-2626	97	2	-	-	NUM
dti-2626	97	3	597	597	NUM
dti-2626	97	4	.	.	PUNCT
dti-2626	98	1	crossref	crossref	PROPN
dti-2626	98	2	pubmed	pubmed	PROPN
dti-2626	98	3	7	7	PROPN
dti-2626	98	4	.	.	PUNCT
dti-2626	98	5	reck	reck	PROPN
dti-2626	98	6	m	m	PROPN
dti-2626	98	7	,	,	PUNCT
dti-2626	98	8	rodríguez	rodríguez	NOUN
dti-2626	98	9	-	-	PUNCT
dti-2626	98	10	abreu	abreu	PROPN
dti-2626	98	11	d	d	PROPN
dti-2626	98	12	,	,	PUNCT
dti-2626	98	13	robinson	robinson	PROPN
dti-2626	98	14	ag	ag	PROPN
dti-2626	98	15	,	,	PUNCT
dti-2626	98	16	et	et	PROPN
dti-2626	99	1	al	al	PROPN
dti-2626	99	2	.	.	PROPN
dti-2626	99	3	five	five	NUM
dti-2626	99	4	-	-	PUNCT
dti-2626	99	5	year	year	NOUN
dti-2626	99	6	outcomes	outcome	NOUN
dti-2626	99	7	with	with	ADP
dti-2626	99	8	pembrolizumab	pembrolizumab	NOUN
dti-2626	99	9	versus	versus	ADP
dti-2626	99	10	chemotherapy	chemotherapy	NOUN
dti-2626	99	11	for	for	ADP
dti-2626	99	12	metastatic	metastatic	ADJ
dti-2626	99	13	non	non	ADJ
dti-2626	99	14	-	-	ADJ
dti-2626	99	15	small	small	ADJ
dti-2626	99	16	-	-	PUNCT
dti-2626	99	17	cell	cell	NOUN
dti-2626	99	18	lung	lung	NOUN
dti-2626	99	19	cancer	cancer	NOUN
dti-2626	99	20	with	with	ADP
dti-2626	99	21	pd	pd	PROPN
dti-2626	99	22	-	-	PUNCT
dti-2626	99	23	l1	l1	PROPN
dti-2626	99	24	tumor	tumor	NOUN
dti-2626	99	25	proportion	proportion	NOUN
dti-2626	99	26	score	score	NOUN
dti-2626	99	27	≥	≥	NOUN
dti-2626	99	28	50	50	NUM
dti-2626	99	29	.	.	PUNCT
dti-2626	100	1	j	j	PROPN
dti-2626	100	2	clin	clin	PROPN
dti-2626	100	3	oncol	oncol	PROPN
dti-2626	100	4	.	.	PUNCT
dti-2626	101	1	2021;39(21):2339	2021;39(21):2339	NUM
dti-2626	101	2	-	-	SYM
dti-2626	101	3	2349	2349	NUM
dti-2626	101	4	.	.	PUNCT
dti-2626	102	1	crossref	crossref	PROPN
dti-2626	102	2	pubmed	pubmed	PROPN
dti-2626	102	3	dti_2626	dti_2626	PROPN
dti-2626	102	4	_	_	PUNCT
dti-2626	103	1	v4.indd	v4.indd	PROPN
dti-2626	103	2	112dti_2626	112dti_2626	NUM
dti-2626	104	1	_	_	PUNCT
dti-2626	104	2	v4.indd	v4.indd	PROPN
dti-2626	104	3	112	112	NUM
dti-2626	104	4	10/23/2023	10/23/2023	NUM
dti-2626	104	5	10:06:57	10:06:57	NUM
dti-2626	104	6	am10/23/2023	am10/23/2023	NOUN
dti-2626	104	7	10:06:57	10:06:57	NUM
dti-2626	104	8	am	be	AUX
dti-2626	104	9	inno	inno	PROPN
dti-2626	104	10	et	et	PROPN
dti-2626	104	11	al	al	PROPN
dti-2626	104	12	drug	drug	PROPN
dti-2626	104	13	target	target	NOUN
dti-2626	104	14	insights	insight	NOUN
dti-2626	104	15	2023	2023	NUM
dti-2626	104	16	;	;	PUNCT
dti-2626	104	17	17	17	NUM
dti-2626	104	18	:	:	SYM
dti-2626	104	19	113	113	NUM
dti-2626	104	20	©	©	PROPN
dti-2626	104	21	2023	2023	NUM
dti-2626	104	22	the	the	DET
dti-2626	104	23	authors	author	NOUN
dti-2626	104	24	.	.	PUNCT
dti-2626	105	1	published	publish	VERB
dti-2626	105	2	by	by	ADP
dti-2626	105	3	aboutscience	aboutscience	NOUN
dti-2626	105	4	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-2626	105	5	8	8	NUM
dti-2626	105	6	.	.	PUNCT
dti-2626	106	1	jassem	jassem	PROPN
dti-2626	106	2	j	j	PROPN
dti-2626	106	3	,	,	PUNCT
dti-2626	106	4	de	de	X
dti-2626	106	5	marinis	marinis	NOUN
dti-2626	106	6	f	f	AUX
dti-2626	106	7	,	,	PUNCT
dti-2626	106	8	giaccone	giaccone	PROPN
dti-2626	106	9	g	g	PROPN
dti-2626	106	10	,	,	PUNCT
dti-2626	106	11	et	et	PROPN
dti-2626	106	12	al	al	PROPN
dti-2626	106	13	.	.	PROPN
dti-2626	106	14	updated	update	VERB
dti-2626	106	15	overall	overall	ADJ
dti-2626	106	16	survival	survival	NOUN
dti-2626	106	17	analysis	analysis	NOUN
dti-2626	106	18	from	from	ADP
dti-2626	106	19	impower110	impower110	PROPN
dti-2626	106	20	:	:	PUNCT
dti-2626	106	21	atezolizumab	atezolizumab	NOUN
dti-2626	106	22	versus	versus	ADP
dti-2626	106	23	platinum	platinum	NOUN
dti-2626	106	24	-	-	PUNCT
dti-2626	106	25	based	base	VERB
dti-2626	106	26	chemotherapy	chemotherapy	NOUN
dti-2626	106	27	in	in	ADP
dti-2626	106	28	treatment	treatment	NOUN
dti-2626	106	29	-	-	PUNCT
dti-2626	106	30	naive	naive	ADJ
dti-2626	106	31	programmed	programmed	ADJ
dti-2626	106	32	death	death	NOUN
dti-2626	106	33	-	-	PUNCT
dti-2626	106	34	ligand	ligand	NOUN
dti-2626	106	35	1	1	NUM
dti-2626	106	36	-	-	PUNCT
dti-2626	106	37	selected	select	VERB
dti-2626	106	38	nsclc	nsclc	NOUN
dti-2626	106	39	.	.	PUNCT
dti-2626	107	1	j	j	PROPN
dti-2626	107	2	thorac	thorac	PROPN
dti-2626	107	3	oncol	oncol	ADJ
dti-2626	107	4	.	.	PUNCT
dti-2626	108	1	2021;16(11	2021;16(11	NUM
dti-2626	108	2	):	):	PUNCT
dti-2626	108	3	1872	1872	NUM
dti-2626	108	4	-	-	SYM
dti-2626	108	5	1882	1882	NUM
dti-2626	108	6	.	.	PUNCT
dti-2626	109	1	crossref	crossref	PROPN
dti-2626	109	2	pubmed	pubmed	PROPN
dti-2626	109	3	9	9	PROPN
dti-2626	109	4	.	.	PUNCT
dti-2626	110	1	sezer	sezer	PROPN
dti-2626	110	2	a	a	PRON
dti-2626	110	3	,	,	PUNCT
dti-2626	110	4	kilickap	kilickap	NOUN
dti-2626	110	5	s	s	PROPN
dti-2626	110	6	,	,	PUNCT
dti-2626	110	7	gümüş	gümüş	PROPN
dti-2626	110	8	m	m	PRON
dti-2626	110	9	,	,	PUNCT
dti-2626	110	10	et	et	PROPN
dti-2626	110	11	al	al	PROPN
dti-2626	110	12	.	.	PROPN
dti-2626	110	13	cemiplimab	cemiplimab	PROPN
dti-2626	110	14	monotherapy	monotherapy	NOUN
dti-2626	110	15	for	for	ADP
dti-2626	110	16	first	first	ADJ
dti-2626	110	17	-	-	PUNCT
dti-2626	110	18	line	line	NOUN
dti-2626	110	19	treatment	treatment	NOUN
dti-2626	110	20	of	of	ADP
dti-2626	110	21	advanced	advanced	ADJ
dti-2626	110	22	non	non	ADJ
dti-2626	110	23	-	-	ADJ
dti-2626	110	24	small	small	ADJ
dti-2626	110	25	-	-	PUNCT
dti-2626	110	26	cell	cell	NOUN
dti-2626	110	27	lung	lung	NOUN
dti-2626	110	28	cancer	cancer	NOUN
dti-2626	110	29	with	with	ADP
dti-2626	110	30	pd	pd	PROPN
dti-2626	110	31	-	-	PROPN
dti-2626	110	32	l1	l1	PROPN
dti-2626	110	33	of	of	ADP
dti-2626	110	34	at	at	ADV
dti-2626	110	35	least	least	ADV
dti-2626	110	36	50	50	NUM
dti-2626	110	37	%	%	NOUN
dti-2626	110	38	:	:	PUNCT
dti-2626	110	39	a	a	DET
dti-2626	110	40	multicentre	multicentre	NOUN
dti-2626	110	41	,	,	PUNCT
dti-2626	110	42	openlabel	openlabel	NOUN
dti-2626	110	43	,	,	PUNCT
dti-2626	110	44	global	global	ADJ
dti-2626	110	45	,	,	PUNCT
dti-2626	110	46	phase	phase	NOUN
dti-2626	110	47	3	3	NUM
dti-2626	110	48	,	,	PUNCT
dti-2626	110	49	randomised	randomise	VERB
dti-2626	110	50	,	,	PUNCT
dti-2626	110	51	controlled	control	VERB
dti-2626	110	52	trial	trial	NOUN
dti-2626	110	53	.	.	PUNCT
dti-2626	111	1	lancet	lancet	NOUN
dti-2626	111	2	.	.	PUNCT
dti-2626	112	1	2021;397(10274):592	2021;397(10274):592	NUM
dti-2626	112	2	-	-	SYM
dti-2626	112	3	604	604	NUM
dti-2626	112	4	.	.	PUNCT
dti-2626	113	1	crossref	crossref	PROPN
dti-2626	113	2	pubmed	pubmed	PROPN
dti-2626	113	3	10	10	PROPN
dti-2626	113	4	.	.	PUNCT
dti-2626	114	1	liu	liu	PROPN
dti-2626	114	2	t	t	PROPN
dti-2626	114	3	,	,	PUNCT
dti-2626	114	4	wu	wu	PROPN
dti-2626	114	5	s	s	PROPN
dti-2626	114	6	,	,	PUNCT
dti-2626	114	7	fang	fang	PROPN
dti-2626	114	8	w	w	PROPN
dti-2626	114	9	,	,	PUNCT
dti-2626	114	10	et	et	PROPN
dti-2626	114	11	al	al	PROPN
dti-2626	114	12	.	.	PUNCT
dti-2626	115	1	identifying	identify	VERB
dti-2626	115	2	optimal	optimal	ADJ
dti-2626	115	3	first	first	ADJ
dti-2626	115	4	-	-	PUNCT
dti-2626	115	5	line	line	NOUN
dti-2626	115	6	immune	immune	ADJ
dti-2626	115	7	checkpoint	checkpoint	NOUN
dti-2626	115	8	inhibitors	inhibitor	NOUN
dti-2626	115	9	based	base	VERB
dti-2626	115	10	regiments	regiment	NOUN
dti-2626	115	11	for	for	ADP
dti-2626	115	12	advanced	advanced	ADJ
dti-2626	115	13	nonsmall	nonsmall	NOUN
dti-2626	115	14	cell	cell	NOUN
dti-2626	115	15	lung	lung	NOUN
dti-2626	115	16	cancer	cancer	NOUN
dti-2626	115	17	without	without	ADP
dti-2626	115	18	oncogenic	oncogenic	ADJ
dti-2626	115	19	driver	driver	NOUN
dti-2626	115	20	mutations	mutation	NOUN
dti-2626	115	21	:	:	PUNCT
dti-2626	115	22	a	a	DET
dti-2626	115	23	systematic	systematic	ADJ
dti-2626	115	24	review	review	NOUN
dti-2626	115	25	and	and	CCONJ
dti-2626	115	26	network	network	NOUN
dti-2626	115	27	meta	meta	ADJ
dti-2626	115	28	-	-	PUNCT
dti-2626	115	29	analysis	analysis	NOUN
dti-2626	115	30	.	.	PUNCT
dti-2626	116	1	plos	plos	PROPN
dti-2626	116	2	one	one	NUM
dti-2626	116	3	.	.	PUNCT
dti-2626	117	1	2023;18(4):e0283719	2023;18(4):e0283719	X
dti-2626	117	2	.	.	PUNCT
dti-2626	118	1	crossref	crossref	PROPN
dti-2626	118	2	pubmed	pubmed	PROPN
dti-2626	118	3	11	11	NUM
dti-2626	118	4	.	.	PUNCT
dti-2626	119	1	mazieres	mazieres	PROPN
dti-2626	119	2	j	j	PROPN
dti-2626	119	3	,	,	PUNCT
dti-2626	119	4	drilon	drilon	ADP
dti-2626	119	5	a	a	PRON
dti-2626	119	6	,	,	PUNCT
dti-2626	119	7	lusque	lusque	NOUN
dti-2626	119	8	a	a	DET
dti-2626	119	9	,	,	PUNCT
dti-2626	119	10	et	et	PROPN
dti-2626	119	11	al	al	PROPN
dti-2626	119	12	.	.	PROPN
dti-2626	119	13	immune	immune	ADJ
dti-2626	119	14	checkpoint	checkpoint	NOUN
dti-2626	119	15	inhibitors	inhibitor	NOUN
dti-2626	119	16	for	for	ADP
dti-2626	119	17	patients	patient	NOUN
dti-2626	119	18	with	with	ADP
dti-2626	119	19	advanced	advanced	ADJ
dti-2626	119	20	lung	lung	NOUN
dti-2626	119	21	cancer	cancer	NOUN
dti-2626	119	22	and	and	CCONJ
dti-2626	119	23	oncogenic	oncogenic	ADJ
dti-2626	119	24	driver	driver	NOUN
dti-2626	119	25	alterations	alteration	NOUN
dti-2626	119	26	:	:	PUNCT
dti-2626	119	27	results	result	NOUN
dti-2626	119	28	from	from	ADP
dti-2626	119	29	the	the	DET
dti-2626	119	30	immunotarget	immunotarget	NOUN
dti-2626	119	31	registry	registry	NOUN
dti-2626	119	32	.	.	PUNCT
dti-2626	120	1	ann	ann	PROPN
dti-2626	120	2	oncol	oncol	PROPN
dti-2626	120	3	.	.	PUNCT
dti-2626	121	1	2019;30(8):1321	2019;30(8):1321	NUM
dti-2626	121	2	-	-	SYM
dti-2626	121	3	1328	1328	NUM
dti-2626	121	4	.	.	PUNCT
dti-2626	122	1	crossref	crossref	PROPN
dti-2626	122	2	pubmed	pubmed	PROPN
dti-2626	122	3	12	12	NUM
dti-2626	122	4	.	.	PUNCT
dti-2626	123	1	sabari	sabari	PROPN
dti-2626	123	2	jk	jk	PROPN
dti-2626	123	3	,	,	PUNCT
dti-2626	123	4	leonardi	leonardi	PROPN
dti-2626	123	5	gc	gc	PROPN
dti-2626	123	6	,	,	PUNCT
dti-2626	123	7	shu	shu	PROPN
dti-2626	123	8	ca	ca	PROPN
dti-2626	123	9	,	,	PUNCT
dti-2626	123	10	et	et	PROPN
dti-2626	123	11	al	al	PROPN
dti-2626	123	12	.	.	PROPN
dti-2626	123	13	pd	pd	PROPN
dti-2626	123	14	-	-	PROPN
dti-2626	123	15	l1	l1	PROPN
dti-2626	123	16	expression	expression	NOUN
dti-2626	123	17	,	,	PUNCT
dti-2626	123	18	tumor	tumor	NOUN
dti-2626	123	19	mutational	mutational	ADJ
dti-2626	123	20	burden	burden	NOUN
dti-2626	123	21	,	,	PUNCT
dti-2626	123	22	and	and	CCONJ
dti-2626	123	23	response	response	NOUN
dti-2626	123	24	to	to	ADP
dti-2626	123	25	immunotherapy	immunotherapy	NOUN
dti-2626	123	26	in	in	ADP
dti-2626	123	27	patients	patient	NOUN
dti-2626	123	28	with	with	ADP
dti-2626	123	29	met	meet	VERB
dti-2626	123	30	exon	exon	PROPN
dti-2626	123	31	14	14	NUM
dti-2626	123	32	altered	alter	VERB
dti-2626	123	33	lung	lung	NOUN
dti-2626	123	34	cancers	cancer	NOUN
dti-2626	123	35	.	.	PUNCT
dti-2626	124	1	ann	ann	PROPN
dti-2626	124	2	oncol	oncol	PROPN
dti-2626	124	3	.	.	PUNCT
dti-2626	125	1	2018;29(10):2085	2018;29(10):2085	X
dti-2626	125	2	-	-	SYM
dti-2626	125	3	2091	2091	NUM
dti-2626	125	4	.	.	PUNCT
dti-2626	126	1	crossref	crossref	PROPN
dti-2626	126	2	pubmed	pubmed	PROPN
dti-2626	126	3	13	13	NUM
dti-2626	126	4	.	.	PUNCT
dti-2626	127	1	mayenga	mayenga	PROPN
dti-2626	127	2	m	m	PROPN
dti-2626	127	3	,	,	PUNCT
dti-2626	127	4	assié	assié	PROPN
dti-2626	127	5	jb	jb	PROPN
dti-2626	127	6	,	,	PUNCT
dti-2626	127	7	monnet	monnet	VERB
dti-2626	127	8	i	i	PROPN
dti-2626	127	9	,	,	PUNCT
dti-2626	127	10	et	et	PROPN
dti-2626	127	11	al	al	PROPN
dti-2626	127	12	.	.	PUNCT
dti-2626	128	1	durable	durable	ADJ
dti-2626	128	2	responses	response	NOUN
dti-2626	128	3	to	to	ADP
dti-2626	128	4	immunotherapy	immunotherapy	NOUN
dti-2626	128	5	of	of	ADP
dti-2626	128	6	non	non	ADJ
dti-2626	128	7	-	-	ADJ
dti-2626	128	8	small	small	ADJ
dti-2626	128	9	cell	cell	NOUN
dti-2626	128	10	lung	lung	NOUN
dti-2626	128	11	cancers	cancer	NOUN
dti-2626	128	12	harboring	harboring	NOUN
dti-2626	128	13	met	meet	VERB
dti-2626	128	14	exon-14	exon-14	PROPN
dti-2626	128	15	-	-	PUNCT
dti-2626	128	16	skipping	skip	VERB
dti-2626	128	17	mutation	mutation	NOUN
dti-2626	128	18	:	:	PUNCT
dti-2626	128	19	a	a	DET
dti-2626	128	20	series	series	NOUN
dti-2626	128	21	of	of	ADP
dti-2626	128	22	6	6	NUM
dti-2626	128	23	cases	case	NOUN
dti-2626	128	24	.	.	PUNCT
dti-2626	129	1	lung	lung	NOUN
dti-2626	129	2	cancer	cancer	NOUN
dti-2626	129	3	.	.	PUNCT
dti-2626	130	1	2020;150:21	2020;150:21	NUM
dti-2626	130	2	-	-	SYM
dti-2626	130	3	25	25	NUM
dti-2626	130	4	.	.	PUNCT
dti-2626	131	1	crossref	crossref	PROPN
dti-2626	131	2	pubmed	pubmed	PROPN
dti-2626	131	3	14	14	PROPN
dti-2626	131	4	.	.	PUNCT
dti-2626	132	1	guisier	guisier	PROPN
dti-2626	132	2	f	f	PROPN
dti-2626	132	3	,	,	PUNCT
dti-2626	132	4	dubos	dubo	NOUN
dti-2626	132	5	-	-	PUNCT
dti-2626	132	6	arvis	arvis	NOUN
dti-2626	132	7	c	c	NOUN
dti-2626	132	8	,	,	PUNCT
dti-2626	132	9	viñas	viñas	NOUN
dti-2626	132	10	f	f	NOUN
dti-2626	132	11	,	,	PUNCT
dti-2626	132	12	et	et	PROPN
dti-2626	132	13	al	al	PROPN
dti-2626	132	14	.	.	PROPN
dti-2626	132	15	efficacy	efficacy	NOUN
dti-2626	132	16	and	and	CCONJ
dti-2626	132	17	safety	safety	NOUN
dti-2626	132	18	of	of	ADP
dti-2626	132	19	anti	anti	ADJ
dti-2626	132	20	-	-	ADJ
dti-2626	132	21	pd-1	pd-1	ADJ
dti-2626	132	22	immunotherapy	immunotherapy	NOUN
dti-2626	132	23	in	in	ADP
dti-2626	132	24	patients	patient	NOUN
dti-2626	132	25	with	with	ADP
dti-2626	132	26	advanced	advanced	ADJ
dti-2626	132	27	nsclc	nsclc	NOUN
dti-2626	132	28	with	with	ADP
dti-2626	132	29	braf	braf	NOUN
dti-2626	132	30	,	,	PUNCT
dti-2626	132	31	her2	her2	PROPN
dti-2626	132	32	,	,	PUNCT
dti-2626	132	33	or	or	CCONJ
dti-2626	132	34	met	meet	VERB
dti-2626	132	35	mutations	mutation	NOUN
dti-2626	132	36	or	or	CCONJ
dti-2626	132	37	ret	ret	NOUN
dti-2626	132	38	translocation	translocation	NOUN
dti-2626	132	39	:	:	PUNCT
dti-2626	132	40	gfpc	gfpc	PROPN
dti-2626	132	41	01	01	NUM
dti-2626	132	42	-	-	SYM
dti-2626	132	43	2018	2018	NUM
dti-2626	132	44	.	.	PUNCT
dti-2626	133	1	j	j	PROPN
dti-2626	133	2	thorac	thorac	PROPN
dti-2626	133	3	oncol	oncol	ADJ
dti-2626	133	4	.	.	PUNCT
dti-2626	134	1	2020;15(4):628	2020;15(4):628	NUM
dti-2626	134	2	-	-	SYM
dti-2626	134	3	636	636	NUM
dti-2626	134	4	.	.	PUNCT
dti-2626	135	1	crossref	crossref	PROPN
dti-2626	135	2	pubmed	pubmed	PROPN
dti-2626	135	3	15	15	PROPN
dti-2626	135	4	.	.	PUNCT
dti-2626	136	1	schrock	schrock	PROPN
dti-2626	136	2	ab	ab	PROPN
dti-2626	136	3	,	,	PUNCT
dti-2626	136	4	frampton	frampton	PROPN
dti-2626	136	5	gm	gm	PROPN
dti-2626	136	6	,	,	PUNCT
dti-2626	136	7	suh	suh	PROPN
dti-2626	136	8	j	j	PROPN
dti-2626	136	9	,	,	PUNCT
dti-2626	136	10	et	et	PROPN
dti-2626	136	11	al	al	PROPN
dti-2626	136	12	.	.	PUNCT
dti-2626	136	13	characterization	characterization	NOUN
dti-2626	136	14	of	of	ADP
dti-2626	136	15	298	298	NUM
dti-2626	136	16	patients	patient	NOUN
dti-2626	136	17	with	with	ADP
dti-2626	136	18	lung	lung	NOUN
dti-2626	136	19	cancer	cancer	NOUN
dti-2626	136	20	harboring	harboring	NOUN
dti-2626	136	21	met	meet	VERB
dti-2626	136	22	exon	exon	NOUN
dti-2626	136	23	14	14	NUM
dti-2626	136	24	skipping	skip	VERB
dti-2626	136	25	alterations	alteration	NOUN
dti-2626	136	26	.	.	PUNCT
dti-2626	137	1	j	j	PROPN
dti-2626	137	2	thorac	thorac	PROPN
dti-2626	137	3	oncol	oncol	ADJ
dti-2626	137	4	.	.	PUNCT
dti-2626	138	1	2016;11(9):1493	2016;11(9):1493	NUM
dti-2626	138	2	-	-	SYM
dti-2626	138	3	1502	1502	NUM
dti-2626	138	4	.	.	PUNCT
dti-2626	139	1	crossref	crossref	PROPN
dti-2626	139	2	pubmed	pubmed	PROPN
dti-2626	139	3	16	16	NUM
dti-2626	139	4	.	.	PUNCT
dti-2626	140	1	akinboro	akinboro	PROPN
dti-2626	141	1	o	o	PROPN
dti-2626	141	2	,	,	PUNCT
dti-2626	141	3	vallejo	vallejo	PROPN
dti-2626	141	4	jj	jj	PROPN
dti-2626	141	5	,	,	PUNCT
dti-2626	141	6	nakajima	nakajima	PROPN
dti-2626	141	7	ec	ec	PROPN
dti-2626	141	8	,	,	PUNCT
dti-2626	141	9	et	et	PROPN
dti-2626	141	10	al	al	PROPN
dti-2626	141	11	.	.	PUNCT
dti-2626	142	1	outcomes	outcome	NOUN
dti-2626	142	2	of	of	ADP
dti-2626	142	3	antipd-(l)1	antipd-(l)1	PART
dti-2626	142	4	therapy	therapy	NOUN
dti-2626	142	5	with	with	ADP
dti-2626	142	6	or	or	CCONJ
dti-2626	142	7	without	without	ADP
dti-2626	142	8	chemotherapy	chemotherapy	NOUN
dti-2626	142	9	(	(	PUNCT
dti-2626	142	10	chemo	chemo	NOUN
dti-2626	142	11	)	)	PUNCT
dti-2626	142	12	for	for	ADP
dti-2626	142	13	first	first	ADJ
dti-2626	142	14	-	-	PUNCT
dti-2626	142	15	line	line	NOUN
dti-2626	142	16	(	(	PUNCT
dti-2626	142	17	1l	1l	NUM
dti-2626	142	18	)	)	PUNCT
dti-2626	142	19	treatment	treatment	NOUN
dti-2626	142	20	of	of	ADP
dti-2626	142	21	advanced	advanced	ADJ
dti-2626	142	22	non	non	ADJ
dti-2626	142	23	-	-	ADJ
dti-2626	142	24	small	small	ADJ
dti-2626	142	25	cell	cell	NOUN
dti-2626	142	26	lung	lung	NOUN
dti-2626	142	27	cancer	cancer	NOUN
dti-2626	142	28	(	(	PUNCT
dti-2626	142	29	nsclc	nsclc	NOUN
dti-2626	142	30	)	)	PUNCT
dti-2626	142	31	with	with	ADP
dti-2626	142	32	pd	pd	PROPN
dti-2626	142	33	-	-	PROPN
dti-2626	142	34	l1	l1	PROPN
dti-2626	142	35	score	score	NOUN
dti-2626	142	36	≥	≥	NUM
dti-2626	142	37	50	50	NUM
dti-2626	142	38	%	%	NOUN
dti-2626	142	39	:	:	PUNCT
dti-2626	142	40	fda	fda	PROPN
dti-2626	142	41	pooled	pool	VERB
dti-2626	142	42	analysis	analysis	NOUN
dti-2626	142	43	.	.	PUNCT
dti-2626	143	1	j	j	PROPN
dti-2626	143	2	clin	clin	PROPN
dti-2626	143	3	oncol	oncol	PROPN
dti-2626	143	4	.	.	PUNCT
dti-2626	144	1	2022;40:16_suppl	2022;40:16_suppl	NUM
dti-2626	144	2	,	,	PUNCT
dti-2626	144	3	9000	9000	NUM
dti-2626	144	4	.	.	PUNCT
dti-2626	145	1	crossref	crossref	PROPN
dti-2626	145	2	17	17	NUM
dti-2626	145	3	.	.	PUNCT
dti-2626	146	1	gridelli	gridelli	PROPN
dti-2626	146	2	c	c	PROPN
dti-2626	146	3	,	,	PUNCT
dti-2626	146	4	morabito	morabito	ADJ
dti-2626	146	5	a	a	PRON
dti-2626	146	6	,	,	PUNCT
dti-2626	146	7	cavanna	cavanna	PROPN
dti-2626	146	8	l	l	NOUN
dti-2626	146	9	,	,	PUNCT
dti-2626	146	10	et	et	PROPN
dti-2626	146	11	al	al	PROPN
dti-2626	146	12	.	.	PUNCT
dti-2626	146	13	cisplatin	cisplatin	NOUN
dti-2626	146	14	-	-	PUNCT
dti-2626	146	15	based	base	VERB
dti-2626	146	16	firstline	firstline	ADJ
dti-2626	146	17	treatment	treatment	NOUN
dti-2626	146	18	of	of	ADP
dti-2626	146	19	elderly	elderly	ADJ
dti-2626	146	20	patients	patient	NOUN
dti-2626	146	21	with	with	ADP
dti-2626	146	22	advanced	advanced	ADJ
dti-2626	146	23	non	non	ADJ
dti-2626	146	24	-	-	ADJ
dti-2626	146	25	small	small	ADJ
dti-2626	146	26	-	-	PUNCT
dti-2626	146	27	cell	cell	NOUN
dti-2626	146	28	lung	lung	NOUN
dti-2626	146	29	cancer	cancer	NOUN
dti-2626	146	30	:	:	PUNCT
dti-2626	146	31	joint	joint	ADJ
dti-2626	146	32	analysis	analysis	NOUN
dti-2626	146	33	of	of	ADP
dti-2626	146	34	miles-3	miles-3	NUM
dti-2626	146	35	and	and	CCONJ
dti-2626	146	36	miles-4	miles-4	NUM
dti-2626	146	37	phase	phase	NOUN
dti-2626	146	38	iii	iii	NUM
dti-2626	146	39	trials	trial	NOUN
dti-2626	146	40	.	.	PUNCT
dti-2626	147	1	j	j	PROPN
dti-2626	147	2	clin	clin	PROPN
dti-2626	147	3	oncol	oncol	PROPN
dti-2626	147	4	.	.	PUNCT
dti-2626	148	1	2018;36(25):2585	2018;36(25):2585	NUM
dti-2626	148	2	-	-	SYM
dti-2626	148	3	2592	2592	NUM
dti-2626	148	4	.	.	PUNCT
dti-2626	149	1	crossref	crossref	PROPN
dti-2626	149	2	pubmed	pubmed	PROPN
dti-2626	149	3	18	18	NUM
dti-2626	149	4	.	.	PUNCT
dti-2626	150	1	wolf	wolf	PROPN
dti-2626	150	2	j	j	PROPN
dti-2626	150	3	,	,	PUNCT
dti-2626	150	4	seto	seto	PROPN
dti-2626	150	5	t	t	PROPN
dti-2626	150	6	,	,	PUNCT
dti-2626	150	7	han	han	PROPN
dti-2626	150	8	jy	jy	PROPN
dti-2626	150	9	,	,	PUNCT
dti-2626	150	10	et	et	PROPN
dti-2626	150	11	al	al	PROPN
dti-2626	150	12	;	;	PUNCT
dti-2626	150	13	geometry	geometry	NOUN
dti-2626	150	14	mono-1	mono-1	NUM
dti-2626	150	15	investigators	investigator	NOUN
dti-2626	150	16	.	.	PUNCT
dti-2626	151	1	capmatinib	capmatinib	PROPN
dti-2626	151	2	in	in	ADP
dti-2626	151	3	met	meet	VERB
dti-2626	151	4	exon	exon	PROPN
dti-2626	151	5	14	14	NUM
dti-2626	151	6	-	-	PUNCT
dti-2626	151	7	mutated	mutate	VERB
dti-2626	151	8	or	or	CCONJ
dti-2626	151	9	met	met	AUX
dti-2626	151	10	-	-	PUNCT
dti-2626	151	11	amplified	amplify	VERB
dti-2626	151	12	nonsmall	nonsmall	ADJ
dti-2626	151	13	-	-	PUNCT
dti-2626	151	14	cell	cell	NOUN
dti-2626	151	15	lung	lung	NOUN
dti-2626	151	16	cancer	cancer	NOUN
dti-2626	151	17	.	.	PUNCT
dti-2626	152	1	n	n	PROPN
dti-2626	152	2	engl	engl	PROPN
dti-2626	152	3	j	j	PROPN
dti-2626	152	4	med	med	PROPN
dti-2626	152	5	.	.	PUNCT
dti-2626	153	1	2020;383(10):944	2020;383(10):944	NUM
dti-2626	153	2	-	-	SYM
dti-2626	153	3	957	957	NUM
dti-2626	153	4	.	.	PUNCT
dti-2626	154	1	crossref	crossref	PROPN
dti-2626	154	2	pubmed	pubmed	PROPN
dti-2626	154	3	19	19	NUM
dti-2626	154	4	.	.	PUNCT
dti-2626	155	1	lu	lu	PROPN
dti-2626	155	2	s	s	PROPN
dti-2626	155	3	,	,	PUNCT
dti-2626	155	4	fang	fang	PROPN
dti-2626	155	5	j	j	PROPN
dti-2626	155	6	,	,	PUNCT
dti-2626	155	7	li	li	PROPN
dti-2626	155	8	x	x	PROPN
dti-2626	155	9	,	,	PUNCT
dti-2626	155	10	et	et	PROPN
dti-2626	155	11	al	al	PROPN
dti-2626	155	12	.	.	PROPN
dti-2626	156	1	once	once	ADV
dti-2626	156	2	-	-	PUNCT
dti-2626	156	3	daily	daily	ADJ
dti-2626	156	4	savolitinib	savolitinib	NOUN
dti-2626	156	5	in	in	ADP
dti-2626	156	6	chinese	chinese	ADJ
dti-2626	156	7	patients	patient	NOUN
dti-2626	156	8	with	with	ADP
dti-2626	156	9	pulmonary	pulmonary	ADJ
dti-2626	156	10	sarcomatoid	sarcomatoid	NOUN
dti-2626	156	11	carcinomas	carcinoma	NOUN
dti-2626	156	12	and	and	CCONJ
dti-2626	156	13	other	other	ADJ
dti-2626	156	14	non	non	ADJ
dti-2626	156	15	-	-	ADJ
dti-2626	156	16	smallcell	smallcell	ADJ
dti-2626	156	17	lung	lung	NOUN
dti-2626	156	18	cancers	cancer	NOUN
dti-2626	156	19	harbouring	harbouring	NOUN
dti-2626	156	20	met	meet	VERB
dti-2626	156	21	exon	exon	NOUN
dti-2626	156	22	14	14	NUM
dti-2626	156	23	skipping	skip	VERB
dti-2626	156	24	alterations	alteration	NOUN
dti-2626	156	25	:	:	PUNCT
dti-2626	156	26	a	a	DET
dti-2626	156	27	multicentre	multicentre	NOUN
dti-2626	156	28	,	,	PUNCT
dti-2626	156	29	single	single	ADJ
dti-2626	156	30	-	-	PUNCT
dti-2626	156	31	arm	arm	NOUN
dti-2626	156	32	,	,	PUNCT
dti-2626	156	33	open	open	ADJ
dti-2626	156	34	-	-	PUNCT
dti-2626	156	35	label	label	NOUN
dti-2626	156	36	,	,	PUNCT
dti-2626	156	37	phase	phase	NOUN
dti-2626	156	38	2	2	NUM
dti-2626	156	39	study	study	NOUN
dti-2626	156	40	.	.	PUNCT
dti-2626	157	1	lancet	lancet	PROPN
dti-2626	157	2	respir	respir	VERB
dti-2626	157	3	med	me	VERB
dti-2626	157	4	.	.	PUNCT
dti-2626	158	1	2021;9(10):1154	2021;9(10):1154	NUM
dti-2626	158	2	-	-	SYM
dti-2626	158	3	1164	1164	NUM
dti-2626	158	4	.	.	PUNCT
dti-2626	159	1	crossref	crossref	PROPN
dti-2626	159	2	pubmed	pubmed	PROPN
dti-2626	159	3	dti_2626	dti_2626	PROPN
dti-2626	159	4	_	_	PUNCT
dti-2626	160	1	v4.indd	v4.indd	PROPN
dti-2626	161	1	113dti_2626	113dti_2626	NUM
dti-2626	161	2	_	_	PUNCT
dti-2626	161	3	v4.indd	v4.indd	PROPN
dti-2626	161	4	113	113	NUM
dti-2626	161	5	10/23/2023	10/23/2023	NUM
dti-2626	161	6	10:06:58	10:06:58	NUM
dti-2626	161	7	am10/23/2023	am10/23/2023	NOUN
dti-2626	161	8	10:06:58	10:06:58	NUM
dti-2626	161	9	am	be	AUX